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I.  Introduction 
 
The main task of the medicinal chemist is to design molecules that interact 
specifically with derailed or degenerating processes in a diseased organism, 
translating the available knowledge of pathobiochemical and physiological data into 
chemically useful information and structures (1). Current knowledge of the biological 
and chemical processes underlying diseases is vast and rapidly expanding. In 
particular the unraveling of the genome in combination with, for instance, the rapid 
development of structural biology has led to an explosion in available information and 
identification of new targets for chemotherapy. The task of translating this wealth of 
data into active and selective new drugs is an enormous, but realistic, challenge. It 
requires knowledge from many different fields, including molecular biology, 
chemistry, pharmacology, physiology, and medicine and as such requires a truly 
interdisciplinary approach.  
Ultimately, the goal is to design molecules that satisfy all the requirements for a 
candidate drug to function therapeutically. Therapeutic activity can then be achieved 
by an understanding of and control over structure and reactivity of the candidate drug 
through molecular manipulation. 
 
Metals in Medicine. Our involvement in drug design comes from our interest in the 
development of metal-based chemotherapeutics. The use of metals in medicine is as 
old as human civilization and has, in more recent years, led to the establishment of the 
field of medicinal inorganic chemistry. Initially fuelled by the discovery of the 
cytotoxic activity of cisplatin, the world‟s most widely used chemotherapeutic 
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anticancer drug today, the field has developed into a thriving area of research, now 
with several other notable successes such as the gadolinium-based MRI agents. We 
and others have recently discussed the use of metals in medicine in more 
comprehensive overviews (2-6). The use of metals is attractive as they offer a unique 
spectrum of reactivity and indeed a structural diversity which is not readily available 
to the more common organic-based drugs. The wide range of coordination numbers 
and geometries, accessible redox states, thermodynamic and kinetic characteristics, 
and the intrinsic properties of both the cationic metal ion and ligand itself offer the 
medicinal chemist a wide spectrum of reactivities that can be exploited. The 
(transition) metals provide a rich palette from which to choose from and offer the real 
possibility of the discovery of truly novel drugs with new mechanisms of action (2). 
 
In our group, a major part of our research is devoted to the design of new anticancer 
drugs. Our recent efforts towards the discovery of new platinum-, ruthenium- and 
osmium-based anticancer agents provide the topic for this account and a section is 
devoted to each metal. We focus on recent results from our lab in the context of other 
developments and related research in this field (hence our coverage of the field is 
focused on these areas and is not comprehensive).  
 
Platinum and Ruthenium Anticancer Drugs. In the field of anticancer drug design 
and in particular with metallochemotherapeutics, DNA has most commonly served as 
the major target, either by direct interaction with the drug or indirectly by inhibition 
of DNA synthesis and replication. The anticancer agents thus work by inhibiting cell 
growth and/or by hastening cell death. The cytotoxic effects of complexes are 
experienced by the rapidly dividing tumor cells, but this mode of action invariably 
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means that normal cells (especially rapidly dividing healthy cells of bone marrow, 
gut, and the skin epithelium) are affected as well. This lack of selectivity of cancer 
drugs is one of the main problems of cancer chemotherapy. Addressing this problem 
of selectivity, together with that of (multi)drug resistance, is one of the major goals of 
research in this field. The genomic revolution has identified many new targets, for 
instance elevated levels of particular enzymes in tumor cells or their involvement in 
pathways significant for proliferation, that hold some promise for the development of 
more selective drugs. Other strategies to alleviate systemic toxicity and resistance 
make use of prodrugs that can either be activated locally by an internal stimulus, e.g. 
a physiological difference in the environment (pH, salt concentration, redox potential) 
or an enzyme-catalyzed chemical transformation, or, alternatively, by an external 
stimulus, such as light. Examples of both approaches will be discussed.  
 
Considerations for Metal-Based Drug Design.  Regardless of the target or approach 
chosen, many considerations for drug design apply to all metal-based therapeutics. As 
with organic drugs, the ADME properties (Absorption, Distribution, Metabolism, and 
Excretion) are of prime importance as the pharmacological and pharmacokinetic 
parameters of the drug must be such for the drug to be able to reach the site of action 
in a timely manner, in a sufficient concentration, and be effectively cleared from the 
system (1). Additionally, for a potent and selective drug, the possibility for strong 
association with the intended target preferably via multiple specific interactions 
should be incorporated into the design of the drug. Metal-based drugs have additional 
possibilities for such molecular recognition, as reactive sites might be available that 
can result in direct coordination to the target. In this respect, stereochemical 
arguments play an important role as well.  
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Some aspects of drug design need to be addressed specifically for metal-based 
therapeutics. The reactivity that offers so many options for new mechanisms of action, 
also poses some inherent difficulties in delivering the drug to its target. It is therefore 
important to constrain the reactivity of the complex sufficiently for it to reach its 
target, without being deactivated by reactions with the large number of biomolecules 
encountered along the way. If they are designed to bind directly to the target then the 
compounds should also not be too stable, as too high kinetic inertness in general will 
render them non-toxic. This is a feature that, however, can be harnessed for the design 
of activatable prodrugs. The prodrug approaches briefly mentioned above attempt to 
address these challenges. Other characteristics specific to metal-containing 
compounds that can have a major influence on their cytotoxic properties include 
geometrical isomerism and redox properties. 
 
To understand fully processes such as molecular recognition, reactivity and 
bioactivity, it is therefore imperative to obtain a detailed insight into the 
thermodynamic and kinetic properties of the metal-based anticancer agent at hand. 
An important part of our work is concerned with the study of the coordination 
chemistry of the anticancer drugs under physiological conditions and in the presence 
of biomolecules that can either be the intended target or a possible influence on 
deactivation or activation of the drug. Identification of the key processes for activity, 
such as hydrolysis or photoreduction, and subsequent manipulation by systematic 
ligand variation proved to be valuable for obtaining potent anticancer agents. Indeed, 
the following sections will show that is possible to control metal-ion reactivity for 
drug design. 
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II. Platinum Anticancer Prodrugs: a Photoactivation Strategy 
 
Introduction to Platinum Anticancer Drugs. Platinum anticancer drugs such as the 
archetypical cisplatin and second generation drugs carboplatin and oxaliplatin (Figure 
1) are widely employed in cancer chemotherapy and are amongst the most effective 
chemotherapeutic agents in clinical use. Cisplatin is particularly active against 
testicular cancer and, if tumors are discovered early, an impressive cure rate 
approaching 100% is achieved. The clinical use of cisplatin against this and other 
malignancies is, however, limited. The low efficacy stems from a combination of uni- 
and multi-cellular resistance, poor whole-body or cellular pharmacokinetic profiles, 
and systemic toxicity (7). Dose-limiting side-effects include neuro-, hepato- and 
nephrotoxicity. Hence, much effort has been devoted to the development of new 
platinum drugs and to the elucidation of cellular responses to them to alleviate these 
limitations (8, 9). An excellent review on the current status of platinum-based cancer 
chemotherapy is available (10). Of the various strategies that have been developed 
(11), those using platinum(IV) complexes as prodrugs appear to have particular 
potential (7). Some general properties of metal-based prodrugs are briefly discussed 
below. 
 
Figure 1. Molecular structures of a) some platinum(II)-based anticancer drugs 
currently used in the clinic; b) satraplatin, a platinum(IV) prodrug currently in clinical 
trials. 
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II. A. Prodrug Strategies  
 
Prodrugs are derivatives of drug molecules that undergo an enzymatic or other 
chemical transformation in vivo to release the active parent drug (12), or indeed to 
generate an active species which could not be delivered by itself (e.g. because it is too 
reactive). Prodrug strategies are aimed at improving physicochemical, 
biopharmaceutical and pharmacokinetic properties of pharmacologically-active agents 
(12). Major applications include the ability to improve oral bioavailability, for 
instance by increasing aqueous solubility or lipophilicity, and to achieve site-selective 
drug delivery. The latter is a central aim in cancer therapy: targeting an inactive 
prodrug selectively to tumor cells, followed by its release, so avoiding toxicity to 
normal, healthy tissue (12).  
 Prodrug strategies are common for metal-based anticancer drugs as well; in 
fact cisplatin itself can be regarded as a prodrug since hydrolysis of the Pt–Cl bonds 
activates the drug for DNA binding (Figure 2). Prodrug activation mechanisms of 
metal-based prodrugs are usually different from organic prodrug activation 
mechanisms, which typically involve bioconversion by enzymes (e.g. esterases, 
phophodiesterases, reductive enzymes). Metal-based prodrugs are commonly 
activated by ligand substitution, a change in oxidation state, a photochemical process, 
or combinations of these (Figures 2 and 3). Ligand substitution can result in the 
creation of a (more) reactive site on the metal, as occurs during hydrolysis of 
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cisplatin. Alternatively, substitution can result in the controlled release of a 
biologically active ligand, a typical example being nitric oxide delivery by photolabile 
metal nitrosyls (13), or CO delivery by metal carbonyls (14). Drug activation by 
substitution requires detailed knowledge of exchange kinetics. The ligand exchange 
rates depend not only on the metal employed and its oxidation state, but also on the 
other ligands in the complex (often stereospecifically) and can vary over many orders 
of magnitude. For example, the exchange rates for aqua ligands on metal ions vary 
over some nineteen orders of magnitude, even though the M–OH2 bonds can have 
similar thermodynamic strengths (15, 16). Consideration of exchange kinetics is 
therefore of prime importance in drug design. The timescale of substitution needs to 
be long enough to allow the drug to reach its target site before it is activated, but 
activation needs to take place before excretion, leaving a relatively narrow window. 
Furthermore the ligand exchange rates can depend on pH, the stereochemistry of the 
complex (cf. hydrolysis rates of cisplatin vs its geometric isomer transplatin), and the 
other ligands coordinated to the metal, so providing many options to exert control 
over this process. Such considerations have played a major role in the development of 
ruthenium- and osmium-arene anticancer complexes in our group, a topic that will be 
discussed further in sections III and IV.  
 A redox activation mechanism usually involves a change in oxidation state of 
the metal (but could also be ligand-centered). Typically, the oxidation state changes 
from a state in which ligand exchange is very slow, i.e. the complex is kinetically 
inert, to a state in which ligand exchange can occur. Again, reduction can either result 
in a reactive metal complex, such as reduction of platinum(IV) complexes to yield 
reactive platinum(II) species (7), or in controlled release of bio-active ligands. An 
example of the latter is Co(III) acting as a chaperone for an analogue of marimastat, a 
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cytotoxic inhibitor of matrix metalloproteinases, which is then released upon 
reduction of the metal to Co(II) (17). The redox change can be triggered by the 
properties of the local environment. The cobalt chaperone complexes, for instance, 
exploit high level hypoxia, a property both common in and unique to solid tumors, for 
activation, as low levels of oxygen prevent reoxidation to the inert Co(III) complex. 
Other physiological characteristics that can be used to advantage are the reducing 
environment in the cell, tissue permeability, and pH (18). These properties differ 
between healthy and tumor cells, which provides a strategy for tumor-selective 
activation of the prodrug. Cancer cell selectivity can furthermore be achieved by 
targeting of biomarkers and receptors that are specifically expressed on tumor cell 
surfaces. Additionally, levels of certain enzymes are often elevated in these cells and 
this can also be exploited in targeted prodrug-tumor delivery. Conjugation of a 
bioactive tumor-targeting group to the metal-based prodrug thus provides another 
interesting strategy for tumor cell-selective activation to combat systemic toxicity. 
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Figure 2. Ligand substitution as a prodrug strategy for metallochemotherapeutics; a) 
general scheme of prodrug activation by ligand substitution; hydrolysis of a metal-
halide bond is a typical activation pathway of metal-based anticancer drugs, as 
exemplified by the activation of cisplatin (b) and a ruthenium-arene complex (c). 
 
Photoactivation as a Prodrug Strategy. Alternatively, prodrug activation by ligand 
substitution or redox change can also be brought about by photochemical means (19). 
In general, the combination of light and metal complexes has been widely employed 
in medicine (20). Phototherapy of cancer, i.e. the treatment of a tumor with a drug and 
light, is particularly attractive as it allows for local treatment of the tumor (i.e. site-
specific activation of the photodrug), thereby minimizing the side-effects of 
chemotherapy. Recent advances in laser and fiber optic technologies have made it 
possible now to reach almost any tissue in the body with light of highly defined 
intensity and wavelength, expanding the applicability of this approach beyond only 
those cancers that are easily accessible. A key parameter in these studies is the 
wavelength of the light. In general, for efficient phototherapy, light with wavelengths 
between 300 and 900 nm should be employed, as shorter wavelengths are typically 
damaging to tissue, DNA and proteins, and longer wavelengths are of insufficient 
energy for chemical transformation (19). Within this window, longer wavelengths are 
preferred if deep penetration into tissue is required. Photodynamic therapy (PDT) is a 
common technique used in the clinic that selectively damages tissue of easily 
accessible cancers (e.g. skin, neck and head, mouth, oesophagus, and bladder) by 
using a photosensitizing drug and light. In PDT, a non-toxic photosensitizer 
catalytically generates cytotoxic singlet oxygen after electronic excitation by light. 
This oxygen-dependence for cytotoxicity is a major drawback of PDT as many 
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malignant and most aggressive cancer cells are hypoxic (21). There is therefore an 
incentive to develop photochemotherapy that is not dependent on oxygen. We have 
recently reviewed the different approaches to photochemotherapy with metal-based 
anticancer complexes (19). 
 
Pt(IV) Prodrugs. Platinum(IV) complexes have been widely studied as potential 
prodrugs that avoid the limitations of the cisplatin class of anticancer drugs. Indeed, 
the Pt(IV) compound satraplatin [Pt(cha)Cl2(OAc)2(NH3)] (cha, cyclohexylamine) is 
currently in clinical trials for treatment of hormone-refractory prostate cancer (Figure 
1) (22). Satraplatin is the first orally-bioavailable platinum derivative under active 
clinical investigation and is particularly attractive because of the convenience of 
administration, milder toxicity profile, and lack of cross-resistance with cisplatin. 
These results are promising and support the idea that platinum(IV) complexes offer 
the opportunity to overcome some of the problems associated with cisplatin and its 
analogues.  
In general, the high kinetic inertness of Pt(IV) complexes lowers reactivity and the 
prospect of side reactions (7). In fact, substitution reactions of the ligands take place 
very slowly or not at all under physiological conditions. Hence, intracellular reduction 
to Pt(II), for instance by cellular reducing agents, is thought to be essential for 
cytotoxic activity. In addition, the octahedral geometry of Pt(IV) introduces two extra 
ligand sites, which offer many possibilities for drug design. They can be used to 
modify the pharmacokinetic parameters of the prodrugs, including the rate of 
reduction and lipophilicity, and to allow inclusion of biologically-active ligands that 
either target the complexes to tumor cells or, alternatively, are themselves cytotoxic 
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upon release (7). Recent advances in the design and development of Pt(IV) anticancer 
complexes have been reviewed (7). 
 
An interesting alternative mechanism of activation is the photochemical reduction of 
Pt(IV) to Pt(II) (Figure 3).
 
In addition to photoreduction, photosubstitution and 
photoisomerization can also occur, making the photochemistry of Pt complexes 
difficult to predict and a careful analysis of the photoproducts imperative (21). We 
have been involved particularly in the development of photochemotherapeutic agents 
based on Pt(IV) and the study of their photodecomposition and (subsequent) 
interactions with biomolecules (21). Our aim is the development of Pt(IV) prodrugs 
which are stable towards reduction, non-toxic in the dark and activated only by light 
and not by cellular processes or responses to other stimuli, such as pH or biological 
reducing agents. In the following sections a detailed overview is given on how 
rational ligand variation led to control over metal ion reactivity and to the 
development of highly cytotoxic, selectively activatable platinum anticancer drugs. 
  
Ultimately, for Pt(IV) anticancer drugs, a combination of incorporation of bioactive 
ligands that specifically target cancer cells, control over ligand exchange kinetics, and 
selective activation by light would allow for temporal and spatial control of drug 
delivery and activation. 
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Figure 3. Photoactivation of Pt(IV) complexes as a prodrug strategy for 
metallochemotherapeutics; a) general scheme of prodrug activation by 
photoreduction; b) photosubstitution and photoisomerization are competing 
photoreaction pathways, which can result in different reactive species upon reduction; 
c) an example of a photoactive platinum(IV) diazido complex developed in our lab. 
 
II. B. Photoactivated Platinum Anticancer Drugs 
 
Pt(IV)-Iodido Complexes. The first photoactive Pt(IV) prodrugs were reported by 
Bednarski et al. in the 1990‟s (23). The complex trans,cis-[PtCl2(en)I2] (1; en = 
ethylenediamine) (Figure 4) can be photolyzed with visible light to give species that 
bind to DNA and inhibit the growth of human cancer cells in vitro. The chelating 
ligand en was chosen as a non-labile ligand (as opposed to NH3) to avoid 
photoisomerization to the thermodynamically more stable but originally considered 
inactive trans-isomer (vide infra). This compound, however, suffered from a very 
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limited stability in serum even in the absence of light. Consequently, no difference in 
dark and light toxicity was seen towards human cancer cells. This was most likely due 
to the relatively high reduction potential of this complex, which leads to facile 
intracellular reduction (21). Electron transfer to the metal can readily occur through 
donation to the coordinated iodido ligands (24). The nature of the axial ligand exerts a 
major influence on the reduction potential and indeed, altering these ligands led to 
complexes with better dark stability (23). In the dark, the complex cis,trans-
[Pt(en)I2(OAc)2] (2) (Figure 4) showed no binding of Pt to CT DNA after 6 h, but, on 
irradiation ( irr > 375 nm) resulted in 63% of the platinum being bound to CT DNA 
after 6 h, suggesting photoreduction to Pt(II) and loss of the iodido ligands. The 
electronic spectra of diiodido-Pt(IV) complexes are dominated by relatively low-
energy LMCT transitions, which allow irradiation of these complexes with visible 
light. Cancer cell growth inhibition studies showed a small, but significant difference 
in light and dark cytotoxicity, with a 35% greater growth inhibition activity with 
irradiation. The complex cis,trans-[Pt(en)I2(OH)2] (3) (Figure 4), on the other hand, 
gave rise to very limited DNA platination on irradiation and a smaller enhancement of 
antiproliferative activity (22%). The non-photolyzed complex could, however, be 
chemically reduced quite readily by addition of the major cellular reducing agent 
glutathione ( -L-Glu-L-Cys-Gly; GSH). This led to the conclusion that photolysis 
resulted predominately in photosubstitution rather than photoreduction in this case, 
illustrating the influence of the axial ligands on photodecomposition pathways (23).  
As intracellular reduction mechanisms are important for Pt(II) and Pt(IV) drugs alike, 
the chemical reduction of cis,trans-[Pt(en)I2(OH)2] (3) by GSH was further explored 
under biologically relevant conditions (24), which led to the unexpected detection of a 
long-lived chelate-ring-opened Pt(II) complex capable of forming DNA-Pt adducts.  
 16 
 
These initial results showed for the first time that it is feasible to design 
photoactivated platinum anticancer drugs by proper choice of the coordinating ligands 
(23). Cisplatin exerts its cytotoxic effect through binding to DNA, which is thought to 
be a major target of the Pt(IV) cisplatin-type prodrugs after activation. It is therefore 
important to gain insight into the reactivity of photoactive prodrugs towards DNA and 
model compounds, such as nucleobases and nucleotides. In further collaboration with 
the Bednarski group, we therefore studied the interaction of the photoactive platinum 
complexes 2 and 3 with nucleotides. Stereospecific reactions between guanosine 5′-
monophosphate (5′-GMP) and cis,trans-[Pt(en)I2(OH)2] (3) or cis,trans-
[Pt(en)I2(OAc)2] (2) could be induced by visible light ( irr 457.9 nm) and 
photoactivation could be controlled by the axial ligands, allowing fine-tuning of the 
photoreactivity of this class of complexes (25). NMR studies on nucleotide binding of 
15
N-labelled complexes confirmed the previously-observed differences in DNA 
binding properties of the two complexes and the suggested differences in the 
photolysis mechanism. 1D 
1
H, 2D [
1
H, 
15
N] HSQC and 2D [
1
H, 
15
N] HSQC-TOCSY 
NMR studies of photoreactions of cis,trans-[Pt(en)I2(OH)2] (3) showed that neither 
the dihydroxido complex nor its photosubstitution product mer-[Pt(en)I(OH)3] react 
with 5′-GMP. On the contrary, similar experiments on cis,trans-[Pt(en)I2(OAc)2] (2) 
revealed two steps in the photoactivation. First, photosubstitution of the labile iodido 
ligands resulted in formation of two complexes, trans-[Pt(en)I(OAc)2(OH)] (2s1) and 
cis,trans-[Pt(en)(OH)2Y2] (2s2) (Y might be I
-
 or OH
-
). The latter complex does not 
react any further, but kinetic analysis revealed that in a second photoactivation step 
trans-[Pt(en)I(OAc)2(OH)] (2s1) is photoreduced and the bis-nucleotide adduct  
[Pt(en)(5-GMP-N7)2] (2rG) is observed. 
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The iodido-Pt(IV) complexes thus provided a proof-of-principle being photoactive, 
but the complexes still suffered from slow photoreactions and, importantly, limited 
stability in the dark especially against biological reducing agents such as glutathione, 
which results in undesired toxicity of the anticancer agents in the dark. 
 
Figure 4. Photoactive Pt(IV)-iodido complexes. a) molecular structures of complexes 
1-3; b) influence of visible light on CT DNA binding of 2 and cytotoxicity of 2 
against a TCCSUP human bladder cell line (data from ref. 23); c) NMR studies 
showed that photosubstitution precedes photoreduction in the reaction of 2 with 5′-
GMP upon irradiation. 
 
Pt(IV)-Azido Complexes. We sought to address this issue and reasoned that 
replacement of the iodido ligands for other photolabile ligands could improve stability 
against reducing agents. Pt(IV)-azido coordination complexes are well known to be 
photoactive (26, 27) and previous studies on Pt(IV)-azido photochemistry had shown 
a two-electron reduction from Pt(IV) to Pt(II) with concomitant liberation of two 
unstable azide radicals, which rapidly decompose in water to form N2 (Figure 5) (27). 
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Halide radicals, on the contrary, do not readily decompose in water, and therefore 
recombination to generate the starting material is a competing process. Azides 
therefore promised to be an attractive alternative to iodides for our drug design.  
 
Figure 5. Originally perceived, possible mechanism for photoactivation of 
platinum(IV) diazido complexes. 
 
We synthesized and reported the first crystal structures of Pt(IV)–diazidodiam(m)ine 
compounds and showed that they also could be activated with visible light to give 
rapid and stereospecific binding of the nucleotide 5′-GMP (28) (Figure 6). The X-ray 
crystal structures of cis,cis,trans-[Pt(N3)2(NH3)2(OH)2] (4) and cis,trans-
[Pt(en)(N3)2(OH)2] (5) show that the metal ion has a close to octahedral coordination 
geometry with almost linear azides in cis-position in the equatorial plane. Importantly, 
the complexes are stable in human blood plasma and the presence of even 5 mM GSH 
has little effect on their stability over a period of several weeks. No reactions with 
either 5′-GMP or the dinucleotide d(GpG) occurred over a week at 298 K in the dark, 
further illustrating that these complexes possess the low chemical reactivity that is 
desired in the dark. The electronic absorption spectra of complexes 4 and 5 contain a 
strong LMCT transition centered on 255 nm, but tailing into the visible. Irradiation of 
cis,trans-[Pt(en)(N3)2(OH)2] (5) ( irr
 
457.9 nm, 15 mW) in the presence of 5′-GMP 
resulted in metal coordination of 60% of the nucleotide present after 20 h and the bis-
nucleotide Pt(II) adduct [Pt
II
(en)(5′-GMP-N7)2]
2+
 was identified as the major product. 
Photoreaction with d(GpG) resulted in the rather clean, rapid and stereospecific 
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formation of [Pt
II
(en){d(G
1
pG
2
-N7
1
,N7
2
)2}]
2+
 (charges on the nucleotide are not 
considered). Similar photoreactivity was observed for cis,cis,trans-
[Pt(N3)2(NH3)2(OH)2] (4). Photolysis of the complexes in water alone revealed that 
the photoreaction pathway involved both photoisomerization and photoreduction to 
highly reactive Pt(II) species of the kind implicated as capable of killing cancer cells. 
High power red light ( irr 647.1 nm, 75 mW), which penetrates tissue more 
effectively, was also able to activate the complexes. 
 
Figure 6. a) Molecular structures of Pt(IV)-diazido complexes 4-7; b) X-ray crystal 
structures of a cis- (5) and trans-diazido complex (7). 
 
DNA platination experiments with cis,trans-[Pt(N3)2(OH)2(en)] (5) were performed 
both in the dark and with irradiation in collaboration with the group of Brabec (29). 
DNA platination of a 212 base pair (bp) fragment of plasmid DNA and transcription 
mapping by RNA polymerase in vitro revealed that whereas no DNA binding 
occurred in the dark, DNA binding in the irradiated sample occurred to the same 
extent and produced similar stop sites as cisplatin, appearing at guanine residues  
mainly contained in GG sequences (29). These results indicate that the prodrugs 
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indeed form cisplatin-like reactive intermediates upon irradiation, although other 
reactive species might be formed as well. 
 These promising results prompted us, in collaboration with the groups of 
Woods and Bednarski, to study the photocytotoxicity of platinum diazido complexes 
(30). The effect of photoactivation of cis,trans-[Pt(en)(N3)2(OH)2] (5) and 
cis,cis,trans-[Pt(N3)2(NH3)2(OH)2] (4) on the growth of 5637 human bladder cancer 
cells was quite dramatic. The complexes were non-toxic in the dark (IC50 > 300 M), 
yet irradiation resulted in selective inhibition of cell growth, with IC50 values of 63 (5) 
and 49 (4) M (Figure 7). Growth inhibition by cisplatin, on the other hand, was 
unaffected by light. Importantly, the platinum diazido complexes were equally 
cytotoxic to 5637 and cisplatin-resistant 5637 cell lines, showing no cross-resistance 
with cisplatin. This latter result suggests that the mechanism of action of the 
photoactive drug is actually different from cisplatin. This is an important observation, 
as overcoming tumor resistance is a major goal in anticancer drug design. 
Photoactivation of the prodrug resulted in dramatic changes in cell morphology, i.e. 
shrinking of the cancer cells, loss of adhesion, packing of nuclear material and 
disintegration of the nuclei. Such changes in morphology are not observed with 
cisplatin, providing further evidence that the light-activated complexes cause a very 
different kind of cytotoxicity than cisplatin (30). This suggests that additional 
cytotoxic species not available to cisplatin might be generated.  CT DNA platination 
studies showed that photolysis rates matched closely the rates of irreversible DNA 
platination, indicating that the photolysis products react directly with DNA and 
notably faster than cisplatin, for which the platination rate is determined by slow 
hydrolysis steps.  
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It is important to note here that the activity of the platinum diazido complexes does 
not depend on the presence of oxygen, in contrast to conventional PDT, which is a 
potential advantage, as some tumors are oxygen-deficient. 
 
Figure 7.  Effect of light on the IC50 values for the inhibition of cell growth of various 
cancer cell lines by platinum(IV) diazido complexes. a) toxicity of the cis-complexes 
4 and 5 on human bladder cancer cell lines; b) comparison of cytotoxicities of the cis- 
and trans-isomers 4 and 6 in the dark and upon irradiation; cisplatin is included for 
comparison (data from ref 30). 
 
The photoactive platinum compounds discussed so far have their labile, photo-
induced electron-donating ligands (I
-
, N3
-
) and their nitrogen donor ligands (NH3, en) 
positioned cis with respect to each other. They can therefore, at least in principle, be 
regarded as prodrugs of cisplatin-like complexes. It is well established that whereas 
cisplatin is highly cytotoxic to cancer cells, its trans-isomer, transplatin, is relatively 
non-toxic and clinically ineffective (31). Our observation that the trans-isomer of a 
platinum(IV) diazido complex, trans,trans,trans-[Pt(N3)2(NH3)2(OH)2] (6), is as 
cytotoxic when photoactivated as cisplatin was therefore somewhat unexpected and 
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quite remarkable (Figure 7) (32). The stereochemistry of the octahedral complex was 
again confirmed by X-ray crystallography, and bond lengths and angles comparable to 
the cis-isomer were found. The trans complex has a much higher aqueous solubility 
than its cis-isomer. This is noteworthy as not only the reactivity of the drug needs to 
be tuned, but also other parameters, such as (oral) bioavailability. 
 Complex 6 exhibits an intense LMCT absorption band at 285 nm, which is 
shifted to longer wavelength and is more intense compared to the cis-isomer. 
Irradiation led to the disappearance of this band, indicating loss of azide. 
Photoactivation of the trans-isomer initially resulted in the appearance of new Pt(IV) 
complexes (probably substitution of N3 for OH), as judged by 2D [
1
H, 
15
N] HSQC 
NMR, and after 60 min peaks for Pt(II) species appeared, including trans-
[Pt(NH3)2(OH2)2]
2+
 (6r). However,  after 120 min of irradiation the majority of Pt was 
still in the +4 oxidation state. One of the new Pt(IV) complexes was identified as the 
monoazido species trans,mer-[Pt(N3)(NH3)2(OH)3] (6s), which indicates that the 
azides do not necessarily leave the platinum metal center together (33). Remarkably, 
photoreduction proceeded much faster in the presence of 5′-GMP, and after 1 h over 
75% had converted to the major product, the bis-GMP adduct trans-[Pt
II(5′-GMP-
N7)2(NH3)2]
2+
. The absence of the range of side-products observed on photoactivation 
of trans,trans,trans-[Pt(N3)2(NH3)2(OH)2] (6) alone, suggests that 5′-GMP can readily 
trap reactive intermediates produced during the photoexcitation process. No reaction 
with 5′-GMP is observed without irradiation. These results illustrate the importance of 
studying interactions with biomolecules as part of the attempt to elucidate the 
mechanism of action of these new anticancer complexes. The photoreactivity products 
are remarkable in that they not only form very fast compared to reactions of 
transplatin, but also the formation of bis-guanine adducts is rarely observed for 
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transplatin. The lack of progression from mono- to bis-guanine adducts is thought to 
be responsible for its lack of anticancer activity (32). 
Cytotoxicity studies (32) on HaCaT cells showed that both the cis- and trans-isomers 
of [Pt(N3)2(NH3)2(OH)2] were equally active upon irradiation and as effective as 
cisplatin (Figure 7). Again, the complexes are non-toxic in the absence of light.  A 
„comet‟-assay showed that the complexes produced DNA cross-linking in living cells 
on irradiation. An appreciation of the intensity of exposure to light in these 
experiments, can be obtained from the comparison that the intensity of the UVA 
irradiation used (5 J cm
-2
 for 50 min) is equivalent to about 15-60 min of exposure to 
sunlight at midday in the UK. These results suggest that further studies also on the 
trans-isomers of the platinum diazido complexes are merited. 
 
As systematic ligand variation provides an attractive method to explore and indeed 
tune the properties of metal-based anticancer drugs (see also the section on 
ruthenium-arenes, section III), we tried to improve further our platinum diazido 
prodrug design by varying one of the ammines in trans,trans,trans-
[Pt(N3)2(OH)2(NH3)2] (6) for different N donor ligands, such as aliphatic amines 
(methylamine, ethylamine, cyclohexylamine) and aromatic N donors (pyridine, 
picolines, quinoline and thiazole) (34). Replacement of the ammine by the -acceptor 
pyridine ligand had a dramatic effect. The complex trans,trans-
[Pt(N3)2(NH3)(OH)2(py)] (7) was found to be highly phototoxic (35). In the dark, no 
cytotoxicity towards HaCaT keratinocytes, SH-SY5Y neuroblastoma, cisplatin-
sensitive A2780 and cisplatin–resistant A2780cis human ovarian cancer cells was 
observed, but upon irradiation 7 strongly reduced the viability of the cancer cells 
(Figure 8). In the A2780 cell line, the complex was 80  more toxic than cisplatin 
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under identical conditions, and ca. 15  more effective against the cisplatin resistant 
A2780cis cell line (33). The trans diazido-Pt(IV) complex therefore has remarkable 
cytotoxic properties.  
 
Figure 8.  Complex 7 is non-toxic in the dark, yet shows remarkable cytotoxicity with 
irradiation against several cancer cell lines; cisplatin is included for comparison (data 
from ref 35). 
  
Complex 7 is stable in water, does not react with 5′-GMP in the dark, and only 5% of 
Pt(IV) was reduced by GSH after 21 days. Irradiation of the complex alone in water 
yielded little reduction to Pt(II) and photosubstitution of one or both of the azides was 
observed. In the presence of 5′-GMP, however, rapid photoreduction resulted in the 
formation of the mono-adduct (SP-4-4)-[Pt
II
(5′-GMP-N7)(N3)(NH3)(py)]
+
 (7rG) and 
bis-adduct trans-[Pt
II
(5′-GMP-N7)2(NH3)(py)]
2+
 (7rG2) (Figure 9). These results 
again argue for stepwise (photo)dissociation of the two azides, rather than reductive 
elimination of both azides in a concerted step.  
 Several biological assays pointed to an unusual mechanism of action for 7, 
which is clearly different from cisplatin, as expected from its remarkable cytotoxic 
activity. For example, different levels of p53 and caspase activity were observed. 
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Unusual crosslinks were detected upon DNA platination, mainly intrastrand trans-
guanine Pt(II) adducts. Importantly, DNA repair synthesis of the platinated lesion 
resulting from photo-platination was markedly lower than for cisplatin or transplatin 
(Figure 9) (33). All these results show that trans,trans-[Pt(N3)2(NH3)(OH)2(py)] (7) 
exerts a rather unique cytotoxic effect and render the complex a candidate for use in 
photoactivated cancer chemotherapy. 
 
Figure 9. a) [
1
H, 
15
N] HSQC NMR spectra of 
15
N-labeled 7 and 2 mol equiv of 5′-
GMP after 1 min and 30 min of irradiation (*, 
195
Pt satellites); b) time dependent 
decrease in concentration of 7 and formation of 7rG and 7rG2 c) quantification of in 
vitro DNA repair synthesis using an extract prepared from the repair-proficient HeLa 
cell line. Cisplatin was taken as 100%. Adapted from ref 35. 
 
 A quick survey of the photochemistry of the different complexes described 
above shows that the mechanism of photoactivation and the subsequent nature of the 
observed photoproducts varies from complex to complex and from one geometric 
isomer to another. Photochemical pathways often involve a combination of 
photosubstitution, photoisomerization and photoreduction steps. In general, photolysis 
is rather slow in water and many different products are obtained if the complex is 
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irradiated alone. The presence of nucleophilic biomolecules, on the other hand, can 
have a major influence, as photoreduction is usually rapid and accompanied by 
simpler reaction pathways. NMR methods including 2D [
1
H, 
15
N] NMR spectroscopy 
in particular, have been instrumental in studying the photochemical decomposition of 
the platinum(IV) prodrugs. However, full understanding of the mechanistic pathways 
of photoactivation has not yet been achieved and remains an important goal of this 
research. The influence of biomolecules other than the nucleobase derivatives is still 
relatively unexplored and deserves more attention. Photochemically induced 
interactions with abundant extra- and intracellular constituents, e.g. proteins such as 
serum albumin and cytochrome c, are currently underway in our laboratory. 
Elucidation of photoactivation pathways and, as a result, predictable photochemistry 
would greatly aid further improvement of drug design.  
All things considered, the originally proposed mechanism of a concerted, 
photoinduced reductive elimination of the two azide ligands to give highly reactive 
Pt(II) species and dinitrogen seems somewhat oversimplified. Although this 
mechanism appears to operate under some conditions, other pathways of activation 
should be considered as well. Indeed, recent photodecomposition studies paint a more 
complex picture (36). NMR studies of the UVA-induced photodecomposition of 
cis,cis,trans-[Pt(N3)2(NH3)2(OH)2] (4) under anaerobic conditions do indeed confirm 
N2 formation and photoreduction to Pt(II), but a tentative assignment of the major 
product (ca 56%) as trans-[Pt(NH3)2(OH2)2]
2+
, suggests that photoisomerization 
accompanies photoreduction (36). Surprisingly, O2 was also detected as a product in 
the sealed NMR tube, suggesting that alternative pathways can operate (Figure 10). 
Evidence for the involvement of nitrene intermediates was also obtained. Trapping 
experiments with dimethylsulfide gave rise to an unusual N,N'-bis(ethyl)-
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sulfurousdiamide ligand involving an apparently unprecedented carbon-carbon bond 
formation. This is an intriguing observation since dialkylsulfides (e.g. methionine 
derivatives) are readily available in biological components. The production of 
dioxygen and detection of oxidized sulfur species points to the photochemical 
generation of reactive oxygen species (ROS). Hydroxyl radicals might, for instance, 
result from homolytic cleavage of Pt(IV)-OH bonds upon reduction. The formation of 
nitrenes and ROS might contribute to the mechanism of action of these photoactivated 
platinum anticancer drugs. 
 
Figure 10. Possible photoactivation pathway of 4: mechanism for nitrene formation 
and subsequent trapping with dimethylsulfide (DMS) results in C–C bond formation, 
DMS oxidation and oxygen evolution. 
 
In addition to key factors that have guided improvements in our design of drugs, such 
as stability in the dark and controlled photoactivation, efforts are aimed particularly at 
shifting the absorption band relevant for photoactivation towards higher wavelengths 
for better tissue penetration, while maintaining the stability of the complexes towards 
reducing agents and alike. The latter is key for non-toxicity in the absence of light and 
hence for site-selective activation. As ligand variation can give only a limited 
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bathochromic shift, other strategies need be explored as well. An interesting 
alternative pathway for photoaction would be multiphoton excitation (19). This way, 
for molecules with a large multiphoton cross-section, a higher energy transition may 
be obtained by the absorption of more than one photon of lower energy (19, 37). 
Preliminary studies on some of the platinum(IV) diazido complexes showed no 
photoactivation by two- or three-photon absorption (33). Current efforts are therefore 
directed at increasing the multiphoton cross-section to achieve photoactivation by this 
method. 
 
In summary, the overview given here of our work on photoactive platinum anticancer 
drugs shows how stepwise improvements transformed an interesting lead compound 
into a highly active new anticancer drug. Rational drug design allowed us to tackle 
initial problems of the photoactive prodrugs, such as the limited stability against 
reducing agents and non-selective activation of the drug leading to cytotoxicity also in 
the absence of light. Systematic ligand variation resulted in a high degree of control 
over the reactivity of the prodrug complex and the discovery of a stable, non-toxic 
and selectively photoactivated potent prodrug that is a promising candidate for 
photoactivated cancer chemotherapy. 
III. Ruthenium-Arene Anticancer Drugs 
 
The field of bioorganometallic chemistry (38) has now established itself as an exiting, 
vibrant area of research at the interface of biology and organometallic chemistry (39). 
The compatibility of organometallic compounds with aqueous conditions, water being 
the essential biological component, has long been considered improbable, many 
organometallic compounds being sensitive to water and oxygen. Yet, the gradual 
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discovery of different biomolecules with metal-carbon bonds such as 
methylcobalamin and the enzyme acetyl-CoA synthase has shown that organometallic 
chemistry and biology are not mutually exclusive. Indeed, the development of 
aqueous organometallic chemistry shows that these limitations can be overcome and 
has expanded the toolbox of the medicinal chemist by introducing many structures 
(M–C bonds with –, –, and/or –bonding) and reactivities unique to 
organometallics (40). This expansion of the field is reminiscent of the introduction of 
inorganic drugs to medicinal chemistry by way of cisplatin in the early „70s, which 
has had an enormous impact on medicine and resulted in an active and successful 
research community. Notable examples of the application of organometallic 
compounds to medicinal chemistry include the work of Jaouen on tamoxifen-
derivatives as chemotherapeutics against breast cancer (41) and the development of 
organometallic 
99m
Tc complexes as radioimaging agents by Alberto (42). Our 
contribution to this field has been the study of ruthenium-arene and recently osmium-
arene complexes as potential anticancer drugs (43, 44). 
 
Introduction to Ruthenium Anticancer Drugs. The discovery of the antitumoral 
properties of cisplatin (Figure 1), as discussed above, marked the advent of modern 
medicinal inorganic chemistry (45). The subsequent clinical success of cisplatin and 
related platinum-based anticancer drugs showed the viability of this approach, but the 
limitations associated with the platinum drugs (mainly required or inherent drug 
resistance and severe dose-limiting side effects) provided the impetus for the search 
for alternative chemotherapeutic strategies based on different complexes with other 
metals. The transition metals offer a rich palette to choose from and indeed many 
different transition metal compounds have been explored for potential anticancer 
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activity. Ruthenium, however, stands out as a particularly attractive alternative to 
platinum. The rich and well-established synthetic and coordination chemistry of 
ruthenium compounds combined with the fact that the metal has several oxidation 
states available under physiological conditions, e.g. Ru(II), Ru(III) and Ru(IV) (46), 
make ruthenium compounds in general well-suited for medicinal applications. Indeed, 
ruthenium compounds have been investigated as immunosuppressants, nitric oxide 
scavengers, antimicrobial agents and antimalarials (44, 47). The potential ability of 
ruthenium to mimic iron in binding to various biomolecules, such as human serum 
albumin and the iron-transport protein transferrin, may aid a more effective delivery 
of ruthenium complexes to cancer cells as such rapidly dividing cells have a greater 
demand for iron and over-express transferrin receptors (46). This property may be 
responsible for the markedly lower toxicity of ruthenium-based anticancer agents 
compared to platinum drugs (48). 
Finally, a key advantage of ruthenium-based metallodrugs is the ability to tune the 
metal-ligand exchange kinetics over many orders of magnitude via ligand variation. 
Such influence over kinetic stability is critical for drug development and our work on 
ruthenium-arene anticancer drugs that is described in this section shows that such 
control can indeed be exerted.  
 
The first report on the anticancer properties of ruthenium was published in 1976 when 
the Ru(III) compound fac-[RuCl3(NH3)3] (Figure 11) was found to induce filamentous 
growth of E. coli at concentrations comparable to those at which cisplatin generates 
similar effects (49). This Ru(III) complex and related compounds such as cis-
[RuCl2(NH3)4]Cl illustrated the potential anticancer activity of ruthenium complexes, 
but insolubility prevented further pharmacological use. Since these initial studies, 
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other Ru(III) complexes have been studied for potential anticancer activity, and two 
compounds, NAMI-A (50) and KP1019 (51),  are currently undergoing clinical trials. 
Remarkably, although the structures of NAMI-A ([Him][trans-RuCl4(dmso)(im)], im 
= imidazole) and KP1019 ([Hind][trans-RuCl4(ind)2], ind = indazole) are quite 
similar (Figure 11), they exhibit contrasting therapeutic effects. KP1019 is 
significantly cytotoxic to cancer cells, whereas NAMI-A is virtually devoid of 
cytotoxicity in vitro, but has antimetastatic activity in vivo. Understandably, this 
remarkable difference has spurred a widespread interest in the chemistry of these and 
related Ru(III) complexes, and elucidation of their mechanisms of action. Several 
reviews on this topic are available (46, 48, 52, 53). 
 
Figure 11. Molecular structures of a) fac-[RuCl3(NH3)3], the first reported ruthenium 
complex with anticancer activity, and b) NAMI-A and KP1019, two ruthenium 
compounds currently in clinical trials. 
 
These relatively inert Ru(III) compounds are essentially prodrugs (see section on 
prodrugs above, section II.A): they are „activated by reduction‟ in vivo to their more 
labile and reactive Ru(II) counterparts, which in turn are responsible for the observed 
cytotoxicity (cf. the Pt(IV)/Pt(II) redox couple) (54, 55). With this in mind, we 
concentrated on the design of ruthenium(II) anticancer complexes. Initial studies 
showed that aminophosphine ruthenium(II) complexes were cytotoxic to cancer cells 
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(56), but these complexes suffered from low aqueous solubility and were not further 
pursued (57, 58). We synthesized the organometallic ruthenium(II) half-sandwich 
complex [Ru(
6
-benzene)Cl(Me2NCH2CH2PPh2)](PF6) in which Ru(II) is stabilized 
not only by the phosphine but also by an 
6
-bonded arene ligand. This complex has 
the characteristic „piano-stool‟ geometry typical of half-sandwich Ru(II)-arene 
complexes (57). This structural element turned out to be key to our later discovery of 
potent organometallic ruthenium anticancer drugs. The inclusion or an 
6
-arene in our 
ruthenium anticancer drug design held some promise, since arene ligands are known 
to stabilize ruthenium in its +2 oxidation state and they provide the complex with a 
hydrophobic face, which might enhance biomolecular recognition processes and 
transport of ruthenium through cell membranes. In an attempt to increase the aqueous 
solubility of the ruthenium-arene complexes (an advantage for clinical use) the 
aminophosphine ligand was replaced with N,N-bidentate ethylenediamine (en), which 
indeed resulted in complexes that are reasonably soluble in water (59). Most 
importantly, the new complexes showed significant inhibition of human ovarian 
cancer cell growth and thus led to our discovery of a new family of organometallic 
ruthenium(II)-arene anticancer drugs (59). The study of this family of ruthenium 
anticancer drugs is the topic of this section.  
 
Other active areas of research into the anticancer properties of ruthenium(II) 
complexes, include, amongst several other examples, the related work on RAPTA 
ruthenium-arene complexes by Dyson and coworkers (46, 60). The recent work by 
Meggers et al. (61) shows an interesting departure from the central paradigm of 
utilizing the transition metal in metallotherapeutics for its inherent reactivity. Their 
approach focuses on the use of the metal as a building block, relying on the kinetic 
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inertness of certain coordination/organometallic bonds, for well-defined three-
dimensional bioactive constructs, which are not accessible through purely organic, 
carbon-based compounds (61). The potential of this strategy is underlined by the 
reported organometallic indolocarbazole ruthenium(II) complexes which were 
designed as staurosporine mimetics and are highly cytotoxic towards human 
melanoma cancer cells (62).  
 
III. A. General Features of Ru-Arene Anticancer Drugs 
 
General Structural Features. The general structure of half-sandwich ruthenium(II)-
arene complexes is shown in Figure 12. The structural, stereochemical and electronic 
features of metal-arene complexes have been discussed (63). A typical „piano-stool‟ 
geometry consists of an 
6
-arene occupying three coordination sites of the pseudo-
octahedral complex, leaving the three „legs‟ X, Y and Z available for coordination. 
The sites X and Y can be taken up by two monodentate ligands, but are more 
commonly occupied by a bidentate ligand L with e.g. nitrogen and/or oxygen donor 
atoms (e.g. NN, NO, or OO coordination), typical examples being ethylenediamine 
(en) or acetylacetonate (acac) (Figure 12). The chelating nature of the bidentate ligand 
seems to be advantageous for anticancer activity. Linking two chelating ligands 
together allows for the synthesis of dinuclear ruthenium-arene complexes. 
The sixth and final coordination site Z is usually a halide and endows the molecule 
with a reactive site. The arene ligand, on the other hand, is relatively inert towards 
displacement under physiological conditions (vide infra for some exceptions). As a 
result of this single-site reactivity, the complexes are considered monofunctional, in 
this case meaning that the metal is capable of forming one direct coordinative bond 
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with a biological target. Other additional non-covalent interactions, such as hydrogen 
bonding and -  stacking, are available to some of the complexes and can be 
advantageous for high cytotoxicity. Depending on the nature of both the chelating 
ligand L and ligand Z, the complexes are either neutral, or mono- or dications and as 
such isolated as salts. The charge on the complex and the nature of the anion can have 
a pronounced influence on important pharmacological properties, such as aqueous 
solubility and partition coefficients.  
 
Figure 12. a) General structure of the half-sandwich, piano-stool ruthenium-arene 
complexes; b) X and Y are commonly occupied by a bidentate ligand L giving a 
monofunctional complex; c) tethering of a monodentate ligand to the arene results in a 
bifunctional complex. 
 
The general structure allows the nature of the arene, the type of chelate and the 
monodentate ligand to be varied. This gives access to a vast library of compounds that 
can be synthesized and screened for anticancer activity (see Figure 13 for the cross 
section of ruthenium-arene anticancer agents discussed in this section). Indeed, 
variation of each of the building blocks allows us to modify key thermodynamic and 
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kinetic parameters, and in this way tailor the pharmacological properties of the 
complexes. The general reactivity will be discussed in a following section.  
Whereas the general structure described above can yield monofunctional adducts with 
biomolecules (vide infra), it is interesting to explore bifunctional ruthenium-arene 
complexes as well, as a different profile of reactivity can be expected. The use of a 
monodentate ligand to achieve this is, however, unadvisable as such complexes 
readily undergo substitution reactions and are, as such, unstable in solution. Tethering 
the monodentate ligand to the arene provides an attractive strategy (Figure 12), such 
chelation stabliizes the molecule towards substitution. In this way, we have 
synthesized some nitrogen-containing, bifunctional tethered Ru(II) arene complexes 
(64). Alternatively, if such a N-donor tethered ruthenium-arene is complexed with a 
bidentate chelating ligand, e.g. en, a molecular switch can be designed to work by 
selective by selective ring-opening of the tether under certain conditions (65). 
 
We have also recently explored some ruthenium-arene complexes that depart 
markedly from the general structure described above. For instance, full sandwich 
ruthenium complexes have been synthesized, in which the positions X, Y, and Z are 
taken by an 
6
-arene ring of a biologically-active ligand, such as aspartame, to assess 
the influence of a metal-complex as a modulating substituent on the properties of the 
bioactive ligand (66). 
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Figure 13. Structural diversity: some ruthenium-arene anticancer agents from the 
Sadler lab. 
 
Synthesis. The various synthetic routes to these complexes have been recently 
reviewed (67). Usually, the synthesis involves the reaction of dimeric Ru(II)-arene 
complexes of the type [Ru(
6
-arene)Cl2] with an appropriate (chelating) ligand. The 
dimers are generally prepared by the redox reaction of RuCl3 and a cyclic 1,4-diene as 
arene precursor, but other routes are available as well. The redox reaction between 
RuCl3 and a cyclic 1,4-diene usually gives the ruthenium-arene dimers in high yield 
and purity, but this synthetic route is limited by the commercial availability or ease of 
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synthesis of diene precursors. Thermal displacement of a coordinated arene provides 
another valuable synthetic route. The latter method has been employed for the 
synthesis of ruthenium-arenes with sterically demanding arenes such as 
hexamethylbenzene (hmb) and for the synthesis of amine-tethered complexes (64, 
68). We have also synthesized the 
106
Ru radiolabeled complex [
106
RuCl(en)(
6
-
fluorene)](PF6) (8) to facilitate pharmacological (ADME) studies (69). 
 
Stereochemistry. It is important to note here that the ruthenium-arene complexes are 
inherently chiral if the three legs of the piano-stool are non-equivalent. For instance, 
the use of an N,O-bidentate mixed chelate such as glycine or hydroxyquinoline gives 
rise to a chiral ruthenium centre. Alternatively, the coordination of a secondary amine, 
such as in N-ethyldiaminoethane (Et-en), to a Ru(II)-arene leads to the formation of 
four diastereoisomers with stereogenic centers at nitrogen and ruthenium. This 
realization is important as the enantiomers (diastereomers), in principle, have different 
biological properties. Knowledge of epimerization rates and, if possible, resolution of 
the enantiomers may then be important for formulation and mechanism of action. In 
this light, the stereochemistry of [Ru(
6
-bip)Cl(Et-en)](PF6) (9) (bip, biphenyl) was 
studied in detail (70). The synthesis of [Ru(
6
-bip)Cl(Et-en)](PF6) (9) gave rise to two 
diastereomers (with relative configurations R*RuR*N (A) and S*RuR*N (B), see Figure 
14), which were separable by crystal picking. Dissolution of the diastereomerically-
pure compounds resulted in the dynamic interconversion of the A or B diastereomers, 
resulting in an equilibrium mixture of 72:28 % of R*RuR*N (A) and S*RuR*N (B). The 
preferred isomer has the ethyl-group pointing away from the arene ring, thus 
minimizing steric repulsion. Our studies thus suggested that isomer A (R*RuR*N) is 
thermodynamically preferred, and that each ruthenium complex is in dynamic 
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equilibrium between the A (R*RuR*N) and B (S*RuR*N) configurations. Interestingly, 
the reaction of the diastereomeric mixture with 9-ethylguanine (9-EtG) resulted in the 
formation of a single diastereomeric pair B (S*RuR*N), apparently made possible by 
the facile epimerization at the nitrogen center (Figure 14). This dynamic chiral 
recognition of guanine provides the possibility of highly diastereoselective DNA 
recognition by ruthenium anticancer agents by an induced fit mechanism (70). 
 
Figure 14. Dynamic chiral recognition of 9-ethylguanine by chiral ruthenium-arene 
complex 9. 
 
Hydrophobicity. An important pharmacological characteristic of the complexes is 
their hydrophobicity (partition coefficients), as it is strongly related to both influx and 
efflux of anticancer drugs. Transport and sequestration of ruthenium complexes, i.e. 
drug uptake, into tumor cells may involve both active and passive diffusion, and may 
be mediated by protein receptors. Active drug efflux on the other hand is sometimes 
mediated by P-glycoprotein, a membrane protein that is overexpressed in cancer cells. 
Hydrophobicity is thought to be a major determinant in substrate specificity and is 
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therefore another structural parameter that can be explored and, in principle, 
optimized (71). Additionally, hydrophobic interactions are important in binding to 
biomolecules such DNA and proteins.  
A convenient and easily accessible way to quantify hydrophobicity is the 
determination of the octanol/water partition coefficient (log P) and we have 
determined the hydrophobicity of 13 selected ruthenium-arene complexes (71). As 
expected, hydrophobicity increases with increase of the size of the coordinated arene 
ring, but decreases significantly when the chloride is replaced by neutral ligands such 
as pyridine and 4-cyanopyridine. The latter observation is somewhat counterintuitive 
at first inspection, but correlates with replacement of anionic chloride to yield a 
dicationic complex. The hydrophobicity correlates significantly with the biological 
activity of these complexes (71). 
 
III. B. Cytotoxicity Studies: Towards Establishing Structure-Activity 
Relationships 
 
Our in vitro and in vivo activity studies have been carried out in collaboration with 
Jodrell‟s group at the Western General Hospital in Edinburgh and with the help of 
Oncosense Ltd, and more recently also with the group of Brabec. 
Initial cancer cell growth inhibition tests done on the human ovarian cancer cell line 
A2780 revealed the cytotoxic activity of some of the tested ruthenium-arene 
complexes (59). IC50 values as low as 6 M were obtained for the complexes [Ru(
6
-
bip)Cl(en)](PF6) (10) and [Ru(
6
-bip)Cl(Et-en)](PF6) (9). This was an order of 
magnitude higher than cisplatin (0.5 M in the same test), but comparable to the 
second generation anticancer drug carboplatin, illustrating the potential of this new 
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family of metallo-anticancer drugs. The complexes [Ru(
6
-bip)Cl(en)](PF6) (10) and 
[Ru(
6
-bip)Cl(Et-en)](PF6) (9) did not inhibit the catalytic activity of topoisomerase I 
or II over the concentration range of observed cytotoxicity (1-50 M), making it 
unlikely that the anticancer activity is related to inhibition of these enzymes (59). 
Complexes with other arenes showed slight differences in activity, which already 
indicated that the structure of the arene is important for cytotoxicity. Indeed, 
increasing the size and overall hydrophobicity of the arene increased cytotoxicity and 
IC50 values of 2 and 0.4 M were found for [RuCl(
6
-dha)(en)](PF6) (11) (dha, 
dihydroanthracene) and [RuCl(en)(
6
-tha)](PF6) (12) (tha, tetrahydroanthracene), 
respectively, the latter thus being equipotent to cisplatin  (Figure 15) (67, 72). 
Complexes with three monodentate ligands, i.e. devoid of the chelate, were essentially 
inactive. These complexes are probably too reactive towards components of the cell 
culture medium and/or the cells and do not reach the target site. Indeed, the 
bifunctional tethered complexes [Ru(
6
:
1
-C6H5CH2(CH2)nNH2)Cl2] (n = 1,2) (13a,b) 
possessing two reactive Ru–Cl bonds, are also not cytotoxic against the A2780 cell 
line (64). A more hydrophobic arene and a single ligand exchange site therefore seem 
associated with high cytotoxicity. 
 
Cross resistance profiles of selected Ru(II) arene complexes in cisplatin-resistant 
A2780cis cells and multi-drug-resistant A2780
AD
 cells showed a relatively high 
degree of cross-resistance in A2780
AD
. By contrast, the organometallic complexes 
tested were completely non-cross resistant in A2780cis cells (72) (Figure 15). 
Cross resistance to [Ru(
6
-bip)Cl(en)]PF6 in A2780
AD
 fell from a factor of 38 to only 
three-fold upon co-administration of verapamil, indicating that P-glycoprotein 
mediated active efflux of the anticancer drug was pre-dominantly responsible for the 
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observed cross resistance and could be abrogated by addition of the competitive 
inhibitor. Such behavior is common for lipophilic positively-charged drugs. 
The patterns of activity established in vitro for 10 were mirrored to a large degree in 
vivo, with high activity in an A2780 xenograft together with non-cross-resistance in 
an A2780cis xenograft and a lack of activity in the A2780
AD
 xenograft (72). [Ru(
6
-
bip)Cl(en)](PF6) (10) was further evaluated against a 13-cell line panel (Freiburg 
screen). The results demonstrated a broad spectrum of activity with a “compare-
negative” score versus other common anticancer compounds suggesting a unique 
mode of action (73). Particular sensitivity was noted in a breast cancer cell line 
(401NL) and a non-small cell lung cancer (NSCLC) cell line (LXFL 529L). The 
activity of [Ru(
6
-bip)Cl(en)](PF6) (10) in two other NSCLC cell lines (H520 (3.5 
M) and A549 (3 M)) was similar to cisplatin (9.5 M and 2.6 M, respectively). 
[RuCl(en)(
6
-tha)](PF6) (12) was even more potent with IC50 values of 0.53 and 0.5 
M, respectively. In vivo experiments showed anti-tumor activity of both complexes 
against an A549 xenograft. A preliminary assessment of the potential therapeutic 
index for these agents, showed that liver toxicity is a concern (73). 
 
We recently tested a more extended range of these organometallic Ru(II) complexes 
complexes for cytotoxicity to elaborate on the structure-activity relationships (67). 
Some general trends could be discerned, but the structure-activity relationship turned 
out to be quite complex. Variation of the arene ring revealed that inclusion of polar 
substituents, such as amides, esters and alcohols lowered cytotoxicity. Nonpolar, 
sterically-demanding substituents, however, resulted in more potent complexes with 
IC50 values as low as 3 M (compared to 0.5 M for cisplatin). Fused ring systems 
showed good activity, with the polycyclic aromatic hydrocarbons being the most 
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active, emphasizing the importance of lipophilicity and possible hydrophobic 
interactions with the nucleobases of DNA (vide infra).  
Data for a series of [Ru(
6
-arene)Cl(en)](PF6) complexes with the isomeric p-, o-, and 
m-terphenyls mirrored these observations (74). The complex with the most extended 
arene (p-terphenyl, 14) was the most potent, with potency similar to cisplatin, but is 
not cross-resistant, and a much higher activity than its isomeric complexes. Again, no 
cross-resistance with cisplatin was observed for these complexes (74). 
Variation of the chelated ligand resulted in complexes with vastly differing 
cytotoxicities. Aliphatic diamines generally showed good cytotoxicity (e.g. 9-12), 
provided they contain a primary amine for stereospecific hydrogen bonding with 
guanine (vide infra). 1,2-Diaminobenzene (dab) complexes such as [Ru(
6
-
bip)Cl(dab)]
+
 (15) also showed good activity and, interestingly, dab complexes 
overcome the cross-resistance to A2780
AD
, previously observed for en-containing 
complexes. Bipyridine and phenanthroline derivatives are inactive, again perhaps 
indicating the importance of NH groups.  
Surprisingly,  replacement of the N,N-chelating ligand en by N,O-chelating ligands of 
some amino acids (amino acidates) proved detrimental for activity. Reactivity studies 
indicated that fast hydrolysis rates and a relatively large proportion of a reactive 
aquated species at physiological chloride concentration might be responsible for the 
lack of activity. Finally, complexes with O,O-chelating ligands such as acac and its 
derivatives (16a,b) showed good to moderate activity, despite the lack of hydrogen 
bond donors. Some of the trends described above, but not all, can be explained by the 
general reactivity profile of ruthenium-arene complexes, which will be discussed in 
more detail below.  
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In the series of diamine complexes, changing the monodentate ligand Z from chlorido 
to iodido or even the pseudohalide N3
-
 has little effect on activity, despite significant 
differences in rate and extent of hydrolysis they are all potential leaving groups (59, 
75). This contrasts dramatically with the chlorido and iodido ruthenium(II) arene 
complexes that contain σ-donor/π-acceptor 2-phenylazopyridines (azpy) as N,N-
chelating ligands (17a,b). These chlorido complexes are inactive against the 
A2780 and A549 cell lines (76). Some of the corresponding 
phenylazopyridine/iodido complexes, on the other hand, proved highly cytotoxic 
to the same cell lines (see section on catalytic anticancer drugs and Figure 23) 
(77). These complexes exhibit a different mechanism of cancer cell cytotoxicity, 
involving catalytic redox reactions (vide infra), in which the reactivity is ligand-based 
rather than metal-based. The complexes provide a nice example of how metal ions can 
also tune the reactivity of coordinated ligands, rather than the other way round. The 
use of a transition metal as a modulating substituent of a ligand is an interesting 
strategy and should be explored further. It takes advantage of properties of the metal 
center other than its direct reactivity and is in this way related to the metal-as-scaffold 
approach in which the metal serves the structural function of spatially orienting the 
coordinated ligands (61). 
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Figure 15. Trends illustrating the influence of the arene, the chelate and the leaving 
group on the cytotoxicity of ruthenium-arene complexes developed in the Sadler lab. 
The complexes are not cross-resistant with cisplatin.  
 
The cytotoxicity data cited above and illustrated in Figure 15 show that ligand 
variation can have dramatic effects on the biological activity of these ruthenium-
arenes. Certain trends can be discerned and such structure-activity relationships then 
carry some predictive value for further drug design. An important next step is then to 
rationalize these relationships by correlating biological activity to chemical reactivity.  
Hence, much attention has been given to the study of the reactivity of this family of 
ruthenium-arene anticancer drugs and their interaction with biomolecules that are 
considered a possible target or that can be encountered by the complex before 
reaching its (final) target. 
 
III. C. Reactivity of Ruthenium-Arene Anticancer Drugs 
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Aquation. The principal reactivity of our family of ruthenium-arene complexes is the 
exchange of the leaving group Z, usually a halide, with water to form the more 
reactive aqua complexes (Figure 16). This latter species undergoes substitution 
reactions, for instance DNA nucleobase binding, much faster than the corresponding 
chlorido precursors and is therefore considered as the active species that exerts the 
pharmacological effect. The ruthenium-arene anticancer complexes [Ru(
6
-
arene)Cl(L)] can therefore be regarded as prodrugs (Figure 2). Understanding  the 
thermodynamic and kinetic parameters that govern prodrug activation by aquation 
have been an important part of our research, as detailed knowledge of the factors that 
control such ligand substitutions under physiological conditions is very valuable in 
drug design. The aqueous chemical reactivity of the complexes can be chosen so as to 
balance the inertness required for the drug to reach its target site and minimize attack 
on other sites, yet allow activation necessary for binding to the target (75). 
 
Figure 16. General reactivity of the ruthenium(II)-arenes. Hydrolysis of the Ru–Z 
bond gives the more reactive aqua species. The pKa of the coordinated water molecule 
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is important, as the hydroxido complex is less reactive. The different structures are 
exemplified by the reactivity of [Ru(
6
-bip)Cl(en)]
+
 (10) for which Z = Cl. 
 
The rate of hydrolysis depends strongly on the nature of all three building blocks, i.e. 
the leaving group, the coordinated arene and the chelate, and can be varied over 
several orders of magnitude, opening a time-window of activation. A detailed study of 
the aquation and the reverse, anation reactions of three [Ru(
6
-arene)Cl(en)](PF6) 
complexes (arene = bip (10), dha (11), and tha (12)) showed that the rates of aquation 
(kH2O 1.23 – 2.59  10
-3
 s
-1
, at 298 K and I = 0.1 M) with half-lives of < 10 min are an 
order of magnitude (> 20 times) faster than that of cisplatin (78). The anation 
reactions in the presence of 100 mM NaCl were very rapid (kCl 0.127 – 0.306 M
-1
 s
-1
, 
at 298 K and I = 0.1 M), resulting in small equilibrium constants for aquation (7.3 – 
9.7  10
-3
 M). This is significant for the speciation of the ruthenium complexes under 
physiological conditions (Figure 17). The results indicate that in blood plasma, where 
the [Cl
-
] is high (about 104 mM), the complexes would exist primarily in their 
chlorido forms (> 89%). In contrast, the chloride concentrations are much lower in the 
cell cytoplasm (about 23 mM) and cell nucleus (4 mM) which would increase the 
amount of more reactive aqua species to ca. 30% and 70 %, respectively. As a result, 
the extracellular suppression of aquation followed by activation upon entering the cell 
provides a selective mechanism of activation. 
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Figure 17. Speciation of [Ru(
6
-bip)Cl(en)]
+
 (10) [5 M] in blood plasma, cytoplasm 
and nucleus at equilibrium, based on the equilibrium constants of aquation, pKa, [Cl
-
] 
and pH of the environments. Data from ref 78. 
 
The mean values of the activation parameters for both aquation and anation show that  
S
‡
 is negative, indicative of an associative pathway (78). Density functional theory 
calculations also suggest that aquation occurs via a more associative pathway in an Ia 
 Id mechanistic continuum for which bond-making is of greater importance than 
bond-breaking (75). The electron-accepting effect of the strong -acid arene ligands is 
thought to be responsible for the shift towards a more associative Ia pathway, as it 
increases the charge on the metal (75). Ru(II) in {Ru(
6
-arene)} complexes may 
therefore behave more like a Ru(III) center, which usually reacts via associative 
pathways (79).  
Both aquation and anation reactions are about twice as fast for the dha (11) and tha 
(12) complexes compared to the biphenyl complex 10. Consequently, the hydrolysis 
rates decrease with increase in the electron-accepting ability of the arene, an 
observation that was later confirmed for a more extensive series of compounds (75). 
We also studied the influence of the type of leaving group on the hydrolysis rate and 
found that it has a large effect. For the halides, the aquation rate was found to 
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decrease in the order Cl  Br > I. Replacement of the chloride ligand with the 
pseudohalide N3 even slowed down the hydrolysis rate 40-fold, while changing it for 
leaving groups such as (substituted) pyridines or thiophenol made the hydrolysis too 
slow to observe. Generally, but not always, complexes that readily hydrolyze are 
cytotoxic. An interesting exception to this rule is [Ru(en)(
6
-hmb)(SPh)]
+
 (18), which 
hydrolyzes extremely slowly yet shows significant activity. Closer inspection of the 
reactivity of this and related compounds suggests an „activation-by-ligand-oxidation‟ 
mechanism and led to our studies on ruthenium-sulfenate and -sulfinate complexes 
that will be further discussed below.     
The chelating ligand also influences the hydrolysis rate. In general, the effect on 
substitution reactions depends on the nature of the chelate and the position of the 
ligand relative to the leaving group. The cis-positioning of the en chelate to the 
leaving group in [Ru(
6
-arene)Cl(en)]
+
 slows down the aquation and anation reactions 
due to electronic and steric effects. Replacement of the neutral en ligand by 
monoanionic acac increases the rate and extent of hydrolysis (80). The presence of a 
-acceptor azopyrazole ligand on the other hand decreases the rate of hydrolysis by 
more than an order of magnitude (76).  
The bifunctional amine-tethered ruthenium(II) arene complexes [Ru(
6
:
1
-
C6H5CH2(CH2)nNH2)Cl2] (n = 1,2) (13a,b) show two consecutive hydrolysis steps to 
yield the mono- and bis-aqua complexes (64). At extracellular chloride 
concentrations, the majority of the complexes could be expected to be present as the 
mono-aqua adduct. Equilibrium constants were determined for both steps (for 13b, K1 
= 145 mM K2 = 5.4 mM) and found to be considerably higher than those of cisplatin, 
which also has two reactive sites available.  
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An important characteristic for the activity of the hydrolysis product, the aqua species, 
is the pKa of the coordinated water molecule (Figure 16). Acid dissociation gives the 
hydroxido complex [Ru(
6
-arene)(L)(OH)]
+
 which is less susceptible to substitution 
reactions than the corresponding aqua complex (81). The pKa values of the aqua 
complexes can be determined by UV-Vis or NMR spectroscopy. The pKa value of the 
coordinated water molecule in [Ru(
6
-arene)(en)(OH2)]
+
 was found to be 7.71, 7.89 
and 8.01 for the bip, dha, and tha complexes, respectively (78). This relatively low 
acidity of the water ligand is important, since under physiological conditions only 
small amounts (< 10% of the total Ru(II) arene complexes) are predicted to exist as 
the less reactive hydroxido complexes. Changing the bidentate ligand to monoanionic 
oxygen chelates such as acac or tropolonate increases the pKa further to 9.12 ([Ru(
6
-
p-cym)(OH2)(trop)]
+
) (19H2O) (82) and 9.41 ([Ru(acac)(
6
-p-cym)(OH2)]
+
) 
(16aH2O) (80), most likely as a consequence of electronic effects exerted by the 
ligand on the metal center (82). In contrast, the pKa of the aqua adduct in [Ru(azpyz-
NMe2)(
6
-p-cym)(OH2)]
+ 
(20H2O) (azpyz-NMe2, 4-(1H-pyrazol-3-ylazo)-N,N 
dimethylaniline) is 4.60, indicative of the low electron density at ruthenium and 
consistent with the -acidic nature of the ligand. Indeed, the complex has a low 
affinity for DNA bases (see below) as it would predominately exist in the more inert 
hydroxido form at physiological pH (76). 
 
These results clearly show that the hydrolysis rate, and with that drug activation, and 
the pKa of the aqua adduct can be tuned, a strategy that has previously been successful 
for Pt anticancer drugs. This opens the possibility of drugs with tailor-made 
properties.  As an aside, it is interesting to note that careful control over the kinetics of 
exchange or, alternatively, the redox potential of a drug might ultimately lead to 
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personalized anticancer drugs. The characteristics of the drugs could be adapted to fit 
physical parameters particular to an individual and would allow activation in specific 
cells. If individual variations in response to a certain drug have a genetic basis, 
dividing patients into subgroups with a similar genetic profile would allow more 
efficient treatment, if a series of anticancer drugs with slightly different properties is 
available. 
 
Loss of Coordinated Arene. We previously stated that the arene ligand in 
ruthenium(II)-arene complexes is relatively inert towards displacement under 
physiological conditions. While this is generally true, there are a few exceptions to 
this rule and this type of reactivity can be used to advantage. Weakly bound arenes, 
for instance, can be thermally displaced, a property convenient for the synthesis of 
ruthenium-arene complexes that are not readily available through more common 
synthetic routes. This way, the reaction of a precursor dimer, [RuCl2(etb)]2 (etb, 
ethylbenzoate) (68), with either 3-phenyl-1-propylamine or 2-phenylethylamine 
results in arene replacement and the isolation of the complexes [Ru(
6
:
1
-
C6H5CH2(CH2)nNH2)Cl2] (n = 1,2) (13a,b) in which the amine tether is coordinated to 
ruthenium as well (64). 
The nature of the chelating ligand exerts a strong influence on the lability of the 
coordinated arene. The presence of strong -acceptor chelate ligands in [Ru(
6
-
arene)Cl(L)]
+
 where L is an azopyridine (17) or azopyrazole (20), can lead to thermal 
displacement of the arene under mild conditions (low temperatures, aqueous solution) 
The arene loss is significant, up to 67 % after 24 hours at 310 K, depending on the 
arene. The competition for -electron density with the -acceptor chelate ligands is 
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responsible for the weakening of the Ru(II)-arene bonds and subsequent loss of the 
arene (76). 
Alternatively, the arene displacement can also be photo- rather than thermally-
induced. In this respect, we studied the photoactivation of the dinuclear ruthenium-
arene complex [{RuCl(
6
-indane)}2( -2,3-dpp)]
2+
 (2,3-dpp, 2,3-bis(2-
pyridyl)pyrazine) (21). The thermal reactivity of this compound is limited to the 
stepwise double aquation (which shows biexponential kinetics), but irradiation of the 
sample results in photoinduced loss of the arene. This photoactivation pathway 
produces ruthenium species that are more active than their ruthenium-arene precursors 
(Figure 18). At the same time, free indane fluoresces 40 times more strongly than 
bound indane, opening up possibilities to use the arene as a fluorescent marker for 
imaging purposes. The photoactivation pathway is different from those previously 
discussed for photoactivated Pt(IV) diazido complexes, as it involves 
photosubstitution rather than photoreduction. Importantly, the photoactivation 
mechanism is independent of oxygen (see section II on photoactivatable platinum 
drugs) (83).  
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Figure 18. The dinuclear complex [{RuCl(
6
-indane)}2( -2,3-dpp)]
2+
 (21) can be 
photoactivated to yield highly reactive and potentially cytotoxic ruthenium species 
and the arene indane, which could be used as a fluorescent probe. 
  
Interactions with Nucleobases. Although it has not yet been unequivocally 
established, the primary cellular target for these organometallic Ru(II) complexes is 
thought to be DNA, as for many metal-based anticancer drugs including the 
archetypal drug cisplatin. The study of this interaction and its possible significant 
effects on DNA structure has therefore been of prime importance in our studies of the 
ruthenium-arene complexes. Initial studies showed a strong selective binding to N7 of 
the guanine bases (the most electron-dense site on DNA) on a DNA 14-mer 
oligonucleotide (59). To gain additional insight into the potential modes of 
interaction, we have studied in depth the binding of the ruthenium-arene complexes 
with nucleic acid derivatives as models of DNA. A detailed study of the complexes 
([Ru(
6
-arene)Cl(en)]
+
) (arene = bip, dha, tha (10-12)) with the guanine derivatives 9-
ethylguanine (9-EtG), guanosine (Guo), and 5′-guanosine monophosphate (5′-GMP) 
both in the solid state (by X-ray crystallography) and in solution (by NMR studies) 
elucidated the interactions that give rise to such high specificity (84). Non-covalent 
interactions turned out to play key roles in the biological molecular recognition 
process. In addition to direct monofunctional coordination of ruthenium to N7, the 
crystal structures of [Ru(
6
-dha)(en)(9-EtG)]
+
 and [Ru(en)(9-EtG)(
6
-tha)]
+
 also 
show strong arene-nucleobase stacking and strong stereospecific intramolecular H-
bonding. The hydrogen bonding interaction and the arene-base stacking are illustrated 
in Figure 19.  
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Figure 19.  The combination of a) a strong stereospecific hydrogen bonding 
interaction of the C6O carbonyl of 9-EtG with an en NH in [Ru(
6
-dha)(en)(9-EtG)]
+
 
and b) a strong -  arene-nucleobase stacking interaction is responsible for the high 
preference of G over A observed for such ruthenium-arene complexes. 
 
The -  stacking interaction between the outer ring of dha and tha and the guanine 
base is close to ideal, with interplanar distances and dihedral angles of 3.45 Å/3.3 ° 
(tha) and 3.31 Å/3.1° (dha). The extensive arene-nucleobase stacking in the absence 
of arene-arene or base-base stacking in [Ru(
6
-arene)(en)(G-N7)]
+ 
represented a new 
structural feature in adducts of metal-based anticancer drugs with nucleobases. The 
observed stacking indicates the potential of ruthenium-arenes for intercalation or 
hydrophobic interactions of the arene ring with duplex DNA (84). Such hydrophobic 
interactions could provide a major contribution to the driving force for DNA binding. 
Comparison of the conformations of the G-adducts with the parent chlorido-
complexes revealed a significant reorientation and conformational change of the 
arene, as a result of the arene-nucleobase interaction. The changes involve rotation 
around the arene-Ru -bonds, twisting around the Ph–Ph bond (bip), and ring bending 
(dha, tha). The arene ligands thus possess the flexibility to optimize the geometry for 
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simultaneous covalent binding and arene-base stacking. This may reduce the steric 
demands of the Ru drug and enhance the DNA affinity. 
 
The second strong non-covalent interaction observed was the stereospecific H-
bonding of an amine NH to the C6O carbonyl of G (average N O distance 2.8 Å, N–
H O angle 163°). This strong H-bonding interaction partly accounts for the high 
preference for binding of {Ru(
6
-arene)(en)}
+
 to G versus A. Indeed, subsequent 
studies on the thermodynamics and kinetics of binding of ([Ru(
6
-arene)Cl(en)]
+
) 
(arene = bip, dha, tha) to mononucleotides and mononucleosides (G, A, C, and T) 
confirmed the importance of these specific interactions. For the mononucleosides, 
selective binding to N7 of guanosine (100%), moderate binding to N3 of thymidine 
(35%), weak binding to N3 of cytidine (14%), and hardly any binding to adenosine (< 
5% to N1/N7) was observed (81). Similar affinities for Ru were found for the 
corresponding mononucleotides, except for an additional, significant amount (40-
60%) of 5′-phosphate binding with 5′-AMP, 5′-CMP, and 5′-TMP, but not with 5′-
GMP (although initially phosphate bound intermediates were detected for 5′-GMP, 
bound phosphate was displaced by N7). No binding to the phosphodiester groups of 
3′,5′-cyclic guanosine monophosphate (3′,5′-cGMP) or 3′,5′-cAMP was observed, 
suggesting that the complexes do not bind to the phosphodiester backbone of DNA. 
Kinetic experiments also indicated that the binding of Ru(II) arene complexes with 
arenes that can take part in -  stacking (dha, tha, bip) are up to an order of 
magnitude faster than those containing arenes which cannot (p-cym (22), bz). This 
demonstrates the significant role arene-purine base-stacking plays in stabilizing the 
transition state in the associative substitution reactions. 
 
 55 
The differences in the extent of binding to Ru(II) can be explained by analyzing the 
possible H-bonding and nonbonding repulsive interactions, in addition to the 
electronic properties of the nucleobase binding sites themselves. We previously saw 
the contribution of non-covalent interactions of amino Ru-arenes with the exocyclic 
carbonyl group of G. In contrast, adenosine has a C6 NH2 group and as a consequence 
binding at either N7 or N1 is weakened by repulsive interactions. The reactivity of the 
various binding sites of the nucleobases decreases in the order G(N7) > T(N3) > 
C(N3) > A(N1, N7). This strong preference for G was confirmed by competition 
studies with 5′-GMP versus either 5′-AMP or 5′-CMP or 5′-TMP; in each case, 
essentially only the 5′-GMP adduct forms. The ability of the NH proton of en to act as 
an H-bond donor toward an exocyclic oxo group but not toward an amino group 
therefore plays an important role in the selective site recognition of these ruthenium-
arene anticancer complexes (81). Extensive NMR studies mirrored the observations 
made for the solid state structures of the ruthenium-arene nucleobase adducts. 
1
H 2D 
NOESY NMR experiments, for instance, confirm that the pendant phenyl ring in 
[Ru(
6
-bip)(en)(9EtG-N7)]
+
 adopts a syn conformation with respect to the G base. 
It is therefore not surprising that replacement of en by acac results in changes in the 
nucleobase selectivity. The complex [Ru(acac)Cl(
6
-p-cym)] (16a) binds equally well 
to guanosine and adenosine and no binding to either thymidine or cytidine was 
observed (80). The N7/N1 coordination ratio for adenosine binding was about 4:1 at 
pH 5.8. Molecular models demonstrate that adenine coordination can be stabilized by 
hydrogen bonding between N6H2 as a donor and an acac oxygen as hydrogen-bond 
acceptor. This hydrogen bonding interaction was later observed in the crystal structure 
of [Ru(
6
-p-cym)(9-EtA)(Ph2acac)]
+
 (16b) (Ph2acac, diphenylacetylacetonate) (85). 
In contrast, the crystal structure of [Ru(
6
-p-cym)(9-EtG)(Ph2acac)]
+
 reveals a 
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repulsive interaction between the exocyclic C6O carbonyl and the acac oxygen, which 
further explains the weaker affinity for G compared with the en complexes (85). 
Indeed, competitive binding of Guo and Ado showed a slightly higher affinity for 
Ado, but the adducts were found to be kinetically labile. 
 
Interactions with Oligonucleotides. Binding studies of ruthenium-arene complexes 
with oligonucleotides have provided insight into their modes of interaction with 
duplex DNA. The reaction of [Ru(
6
-bip)Cl(en)]
+
 (10) with the single-strand DNA 
14-mer d(ATACATGGTACATA) or its complementary strand 
d(TATGTACCATGTAT) gave rise to mono-ruthenated and/or di-ruthenated species 
depending on the Ru:oligonucleotide ratio, consistent with selective binding at G (86). 
Surprisingly, when a ruthenated single strand was annealed with its complementary 
strand, the product was not simply a double strand ruthenated at a single site. 2D 
NOESY NMR data showed that all four guanine residues were ruthenated at N7. 
Hence, we concluded that ruthenation is indeed highly specific, but also that {Ru(
6
-
bip)(en)}
2+
 is mobile at elevated temperatures (353 K) and migration between guanine 
residues can be facile. This contrasts with observations for DNA with bound Pt(II) 
am(m)ines for which migration is rare.  
Intramolecular NOEs and other NMR data were consistent with arene ring 
intercalation between DNA bases. Molecular models suggested two different 
interactions (Figure 20). One in which the ruthenium complex was bound to G and its 
pendant arene ring is intercalated between a G and T residue, and a second in which 
the ruthenium arene is stacked on a flipped-out T on the surface of the major groove, 
i.e. is non-intercalated, forcing a T base to stack underneath it by tilting. Furthermore 
the data suggest that arene intercalation is dynamic: equilibria can exist between the 
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intercalated and non-intercalated conformers. We also reported on the ruthenation of 
single- and double-stranded self-complementary hexameric DNA (d(CGGCCG)) (87). 
The complexes [Ru(
6
-arene)Cl(en)]
+
, arene = p-cym (22) and bip (10), in this study 
were chosen to compare potential intercalators (bip) with non-intercalators (p-cym). 
For ss-DNA, all three G‟s were readily ruthenated, but for duplex DNA a preferential 
ruthenation of G3 and G6, and no binding to G2 was detected. This was attributable to 
unfavorable steric interactions between the duplex and arene for binding at G2. The 
differences between the two arenes manifested themselves in different strengths of 
hydrogen bonding between the amine NH to the C6O carbonyl of G. The intercalation 
of the pendant phenyl ring in the bip adduct resulted in weakening of the 
stereospecific hydrogen bond compared to the p-cymene adduct. The arene ligand 
plays a major role in distorting the duplex either through steric interaction (p-cymene) 
or through intercalation (biphenyl) (87). 
This work provides important evidence for elucidating the cytotoxic effect of the 
ruthenium-arene complexes and the influence of the arene thereon, for instance with 
respect to excision repair of DNA lesions and DNA destabilization. It also established 
two different classes of Ru(II) arene anticancer drugs, i.e. those bearing an arene that 
has the possibility to intercalate and those that do not. This distinction is important as 
we will see further differences in DNA binding interactions for these two classes (vide 
infra). 
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Figure 20. Molecular models of two conformers of 14-mer duplex 
d(ATACATGGTACATA)  ruthenated at N7 of one of the guanine residues with 
[Ru(
6
-bip)Cl(en)]
+
  (10). Conformer a) shows the nonintercalated phenyl ring of the 
arene stacked on a thymine residue. 
 
Interactions with DNA. In collaboration with the Brabec group, we studied the DNA 
interactions of several organometallic [RuCl(
6
-arene)(en)]
+
 complexes in cell-free 
media. Binding studies using calf thymus (CT) double-helical DNA (ri = 0.1) showed 
that the bip, dha, and tha complexes 10-12 bind about an order of magnitude faster 
than cisplatin, with t½ values of 10, 15, and 10 min, respectively (88). The influence 
of the arene is remarkable as for p-cymene (22) a t½ of 3.5 h was obtained. These 
results correlate well with the ability of the arene for intercalation/ -  stacking. DNA 
binding was almost quantitative and irreversible and transcription mapping 
experiments identified G as the preferential binding site, consistent with our previous 
studies on the DNA models. DNA binding of the achiral Ru(II) complexes with bip, 
dha, or tha as the arenes induced a sizeable circular dichroism (CD) spectrum for 
Ru(II)-arene absorption bands, whereas p-cym binding did not result in an induced 
CD band. Linear dichroism (LD) data showed that the p-cym complex stiffened DNA, 
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while the other complexes bend it. Differential pulse polarography measurements 
demonstrated nondenaturational alterations in DNA with bip, dha, and tha and 
denaturational alterations with p-cym (88). All these observations point to differences 
in binding interactions between ruthenium-arene complexes that can intercalate and 
those that cannot. Interestingly, the adducts of the p-cym complex distort the 
conformation and thermally destabilize DNA distinctly more that the other three 
adducts (88). This is remarkable since an intercalating arene enhances cytotoxicity in 
a number of tumor cell lines (59, 89). It is known that biological activity is modulated 
by the „downstream‟ effects of damaged DNA, such as recognition of damaged DNA 
by specific proteins and/or repair. The different distortions might lead to different 
„downstream‟ effects, which could eventually explain the differences in observed 
cytotoxicity.  
Further experiments focused therefore on [RuCl(en)(
6
-tha)]
+
 (12) and [RuCl(
6
-p-
cym)(en)]
+
 (22), which represent the two different classes, and their conformational 
distortion of short oligonucleotide duplexes. Chemical probes demonstrated that the 
induced distortion extended over at least 7 basepairs for [RuCl(
6
-p-cym)(en)]
+
 (22), 
whereas the distortion was less extensive for [RuCl(en)(
6
-tha)]
+
 (12). Isothermal 
titration calorimetry also showed that the thermodynamic destabilization of duplex 
was more pronounced for [RuCl(
6
-p-cym)(en)]
+
 (22) (89). DNA polymerization was 
markedly more strongly inhibited by the monofunctional Ru(II) adducts than by 
monofunctional Pt(II) compounds. The lack of recognition of the DNA 
monofunctional adducts by HMGB1, an interaction that shields cisplatin-DNA 
adducts from repair, points to a different mechanism of antitumor activity for the 
ruthenium-arenes. DNA repair activity by a repair-proficient HeLa cell-free extract 
(CFE) showed a considerably lower level of damage-induced DNA repair synthesis 
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(about 6 times) for [RuCl(en)(
6
-tha)]
+
 compared to cisplatin. This enhanced 
persistence of the adduct is consistent with the higher cytotoxicity of this compound 
(89). 
DNA binding studies on the series of isomeric [Ru(
6
-arene)Cl(en)]
+
 compounds with 
o-, m- or p-terphenyl as the arene further illustrate the importance of the 
hydrophobicity and intercalation potential of the arene. The more extended p-
terphenyl isomer 14 showed faster binding, a larger unwinding angle and a more 
significant distortion of the duplex compared to the m-terphenyl isomer (74). 
The tethered bifunctional complexes [Ru(
6
:
1
-C6H5CH2(CH2)nNH2)Cl2] (n = 1,2) 
(13a,b) readily bound to CT DNA but failed to produce stop sites on the pSP73KB 
plasmid DNA for RNA synthesis and very low amounts of cross-linking were 
observed, indicating the formation mainly of monofunctional adducts on DNA. This, 
together with a small observed unwinding angle, may explain why these complexes 
exhibit low cytotoxicities (64).  
Dinuclear ruthenium-arene complexes can also bind rapidly to CT DNA, again 
preferentially to G bases. DNA-directed RNA synthesis was inhibited more 
effectively than by the corresponding mononuclear complex (70). A large unwinding 
angle of 31° induced by binding of the dinuclear complex [{RuCl(
6
-bip)}2(en)2-
(CH2)6]
2+
 (23) to pSP3KB DNA, twice that of the mononuclear complex (14°), 
attributable to DNA crosslinking and structure perturbation by the two pendant phenyl 
rings (70). These results illustrate the synergistic effects of tethering the complexes 
together. 
 
Interactions with Biomolecules. Candidate metallodrugs encounter a plethora of 
biomolecules upon administration, be it in, for instance, the blood plasma, the cell 
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membrane, or the cytosol, before they reach the proposed target site (e.g. DNA in the 
nucleus or mitochondrion). The study of the interactions between the metal-based 
anticancer agent and proteins, antioxidants and other cellular components is therefore 
of key importance in understanding both the biological activity both in vitro and in 
vivo. Such interactions can be responsible for drug inactivation (related to resistance) 
or activation (e.g. in the case of prodrugs) and drug delivery. Indeed, the biomolecule 
can even be the actual target of the metallodrug. Whereas the interaction of 
ruthenium-arene complexes with (models of) DNA has been extensively investigated, 
protein interactions are much less well characterized. Advances in particular in mass 
spectrometric methods, in combination with NMR and single crystal X-ray diffraction 
studies, now provide an opportunity to map the interactions of ruthenium-arene 
anticancer drugs with the proteome and identify key protein targets. This area is 
currently attracting much interest (53). 
We reported the first crystal structure of a half-sandwich arene ruthenium(II)-enzyme 
complex (Figure 21) (90). The crystal structure showed a {Ru(
6
-p-cym)X2} half-
sandwich fragment bound selectively to N  of the imidazole ring of the only histidine 
residue (His15) in egg-white lysozyme, a small 14 kDa single-chain protein. The 
electron density for the additional two ligands on ruthenium was modeled as chloride, 
although partial occupancy by water cannot be ruled out. The selective binding of the 
Ru-fragment places the complex in an environment that is asymmetric by nature. 
Since there is much current interest in ruthenium-catalyzed enantioselective synthesis, 
these results suggest that such sites can provide a basis for the design of novel 
catalytic centers (90).  
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Figure 21. X-ray crystal structure of a half-sandwich arene ruthenium(II)-enzyme 
complex: [RuCl2(
6
-p-cym)(lysozyme)] 
 
Horse heart cytochrome c also has two solvent-accessible histidine residues, His26 
(interior residue) and His33 (surface exposed), but our NMR and ESI-MS binding 
studies of [Ru(
6
-bip)Cl(en)]
+
 (10) show no binding to the histidine residues even 
with an 10-fold excess of ruthenium. Monoruthenated enzymes were detected both in 
water (pH 8.7) and buffer (pH 7.6) and ICP-AES revealed that 50 % of cytochrome c 
was ruthenated. Surprisingly, 2D [
1
H, 
15
N] HSQC NMR data suggest that ruthenium 
is bound to the N-terminal amino group or to a carboxylate group (Glu, Asp or C-
terminus), rather than to the histidines (91). 
Histidine residues are, however, generally regarded as major possible binding sites for 
ruthenium-arene complexes in proteins. To model this interaction, we also studied the 
reaction of [RuCl(en)(
6
-bip)]
+
 (10) with L-histidine at 310 K in aqueous solution 
(91). The reaction was quite sluggish and did not reach equilibrium until 24 h at 310 
K, by which only about 22% of the complex had reacted. Two isomeric imidazole-
bound histidine adducts could be discerned, with more or less equal binding through 
N  and N  to ruthenium. Competitive binding experiments of [Ru(
6
-bip)Cl(en)]
+
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with an oligonucleotide and either L-histidine or cytochrome c showed almost 
selective binding to the oligonucleotide and neither the amino acid nor the protein can 
compete effectively with the guanine site in the oligonucleotide (91). 
  
Reaction with sulfur-containing amino acids L-cysteine and L-methionine appear to 
play a major role in the biological chemistry of both Pt(II), Pt(IV) and Ru(III) 
anticancer agents, making it important to study these interactions with Ru(II)-arenes 
as well. [Ru(
6
-bip)Cl(en)]
+
 (10) reacts slowly with L-cysteine with only 50% of the 
complex reacting after 48 h (92). Initially, S- or O-bound 1:1 [Ru(
6
-bip)(L-
Cys)(en)]
+
 adducts are formed after hydrolysis of the chlorido complex. The 
mononuclear adducts then convert to the final products, which could be identified as 
unusual dinuclear ruthenium complexes, in which the one or two en chelates have 
been displaced to form singly or doubly S-bridged adducts. Methionine binding was 
found to be equally slow, with only 23% of the ruthenium complex reacted after 48 h 
to give S-bound [Ru(
6
-bip)(en)(S-L-Met)]
2+
. 
These amino acid and protein binding results might account for the low toxic side 
effects of this class of anticancer agents (72). On the other hand, the relatively weak 
binding to amino acids and proteins could perhaps aid in transport and delivery of 
active species to cancer cells prior to binding to DNA or RNA (75). 
 
Of special interest is the interaction of the family of ruthenium-arenes with the 
tripeptide glutathione ( -L-Glu-L-Cys-Gly; GSH). This major intracellular antioxidant, 
present at millimolar concentrations in the cell, is known for its ability to detoxify 
heavier transition metal ions, including some platinum and ruthenium anticancer 
complexes (93). Given the abundance of GSH in the cell, competition experiments 
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with GSH and cGMP were undertaken to obtain more insight into binding selectivity 
of the ruthenium-arene anticancer complexes and to determine whether a large molar 
excess of GSH could prevent nucleobase binding. Our initial studies on the reaction of 
[Ru(
6
-bip)Cl(en)]
+
 and GSH gave some surprising results (Figure 22) (94). Under 
physiological and anaerobic conditions (20 M [Ru], 5 mM GSH, pH = 7 buffered 
solution, 310 K), the reaction yielded the thiolato adduct [Ru(
6
-bip)(en)(S-GS)]
+
 as 
the major product. Unexpectedly, under an O2 atmosphere, the thiolato adduct fully 
converted to a sulfenato complex in 48 h, strongly suggesting that the sulfenato 
originates from oxidation of the thiolato complex. The sulfenate is likely to be 
coordinated through S rather than O, as indicated by the observed S=O stretching 
frequency. Sulfenates are generally too reactive to be isolated, but can be stabilized by 
coordination to a transition metal. 
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Figure 22. Remarkable „activation-by-ligand-oxidation‟ pathways for the reaction of 
ruthenium-arenes with thiolates. a) reaction of [Ru(
6
-bip)(en)(OH2)]
+
 with GSH; b) 
direct synthesis of ruthenium-arene sulfenato complexes; c) the air-stable thiolato 
complexes are oxidized in the presence of the antioxidant GSH. 
 
Competition experiments with 250 mol equiv GSH and 25 mol equiv cGMP 
subsequently showed that although initially both glutathione (thiolato and sulfenato) 
and cGMP adducts were formed, after 72 hours the cGMP adduct was identified as 
the dominant product of the reaction. Our results indicated that the sulfenato ligand is 
readily displaced by cGMP, whereas the thiolato ligand is not (Figure 22). The 
oxidation to sulfenate (perhaps followed by protonation, vide infra) could possibly 
weaken the ruthenium-sulfur bond and in this way introduce a good leaving group. X-
ray absorption studies that provide insight into the covalency of the metal-sulfur 
bonds of the thiolato, sulfenato and sulfinato complexes are currently under way (95). 
This „activation-by-ligand-oxidation‟ is remarkable and clearly distinguishes these 
complexes from, for instance, cisplatin. It provides a facile route for DNA and RNA 
ruthenation even in the presence of a large excess of GSH (94). These observations 
also shed more light on the activity of [Ru(en)(
6
-hmb)(SPh)]
+
 (18), a complex of 
significant, but also initially somewhat unexpected cytotoxicity, given that the 
complex does not hydrolyze (75). 
We further explored the oxidation of a ruthenium-coordinated thiolate and the 
chemistry of the resulting sulfenato-complexes (Figure 22) (96). Sulfenato complexes 
could be directly obtained from the oxidation of [Ru(
6
-arene)(en)(SR)]
+
 with 
hydrogen peroxide. The resulting sulfenato complexes are stable towards hydrolysis 
at pH 7 at ambient temperature. The ruthenium-sulfenato complex is rather basic (pKa 
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of 3.37 for [Ru(en)(
6
-hmb)(S(O)iPr)]
+
) (24b) and protonation at lower pH leads to 
hydrolysis (96). The thiolato complexes are not sensitive to air, in contrast to the 
analogous GSH adducts. Surprisingly, however, we found that [Ru(en)(
6
-
hmb)(SiPr)]
+
 (24a) could be fully oxidized to [Ru(en)(
6
-hmb)(S(O)iPr)]
+
 (24b) by 
dioxygen in the presence of GSH, with concomitant conversion of the latter to GSSG. 
The oxygen atom transfer from an intermediate of GSH autooxidation to the 
organometallic ruthenium arene thiolato complex was remarkably efficient (97). 
 
Our work on thiolato oxidation is of broader relevance, as there is much current 
interest in the function of protein cysteinyl sulfenates in signal transduction, oxygen 
metabolism, oxidative stress, and their role in the activity of nitrile hydratase (98-
100).  
 
Catalytic Activity of Ruthenium-Arene Complexes. Although a different 
mechanism of action than cisplatin is assumed for the family of cytotoxic ruthenium-
arene compounds, the general reactivity assumed for most of the cytotoxic ruthenium-
arene complexes is consistent with the classic cisplatin paradigm of aquation followed 
by DNA binding, which in turn leads to „downstream‟ effects that ultimately trigger 
apoptosis. The reactivity of the cytotoxic agent is therefore limited to a one-off event. 
It would be desirable to develop metallo-anticancer agents that exert their cytotoxic 
effect in a catalytic manner, rather than the common single reactivity. The possibility 
of multiple turnovers would potentially increase the potency of a drug and thus allow 
lower doses to be administered to the patient.  
The exceptional ability of bioorganometallics to acts as catalysts has not yet been 
widely explored (101). Half-sandwich ruthenium complexes, for instance, are highly 
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active catalysts in a wide variety of chemical transformations, most notably transfer 
hydrogenations, amongst many others. With this in mind, we have studied the 
regioselective reduction of NAD
+
 to NADH by [Ru(
6
-arene)Cl(en)]
+ 
complexes 
using formate as the hydrogen donor under physiological conditions (102). 
NAD(P)
+
/NAD(P)H is one of the major redox couples found in the cell involved in 
many electron transfer reactions. Off-setting the NAD(P)
+
/NAD(P)H  equilibrium by 
catalytic conversion might be a way of exerting a cytotoxic effect through disturbing 
the cell‟s redox state. The reactivity was again found to be highly dependent on the 
arene, with [RuCl(en)(
6
-hmb)]
+
 (25) giving the best results. Turnover frequencies 
were modest (1.46 h
-1
 at saturation, pH 7.4 and 37 °C), however, and formation of the 
ruthenium-hydride species proved rate-limiting. Lung cancer cells were found to be 
remarkably tolerant to formate even at millimolar concentrations, opening up the 
possibility of in vivo biocatalysis if more active organometallic complexes would 
become available (102).  
One point of concern for in vivo activity is that metal-based catalysts might readily be 
inactivated by poisoning. The myriad of cellular components such as thiols that are 
present in millimolar concentrations, e.g. GSH, provide a challenge for 
organometallic complexes. It is therefore intruiging that [Ru(
6
-arene)(azpy)I]
+
 
complexes can act as catalysts for the oxidation of the major intracellular reducing 
agent glutathione to glutathione disulfide, in a cycle which appears to involve ligand-
centered redox reactions (Figure 23) (77). The influence of the halide is remarkable in 
this case as the chloride complex is rather unstable and not cytotoxic/catalytically 
active. The [Ru(
6
-arene)(azpy)I]
+
 complexes do not hydrolyse, but do deplete 
millimolar amounts of GSH over 24 h by catalytic oxidation to GSSG under 
physiological conditions. Concomitant hydrogenation of dissolved dioxygen leads 
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to the formation of hydrogen peroxide and, a reactive oxygen species (ROS), which 
which are thought to be ultimately responsible for the cell death. The catalytic 
ruthenium anticancer agents thus lead to oxidative stress by simultaneously 
producing ROS and consuming its antioxidant defenses in the cell (77). It is important 
to note that the azpy ligands themselves do not show this type of reactivity and the 
ligands are catalytically active only upon coordination to the metal center, i.e. 
controlling ligand reactivity by metal-ion coordination (77). 
 
Figure 23. a) The [Ru(
6
-arene)(azpy)I]
+
 complex (17a) is a catalytically active 
ruthenium-arene anticancer agent; (b) remarkable influence of the leaving group on 
cytotoxic activity; c) [Ru(
6
-arene)(azpy)I]
+
 complexes can act as catalysts for the 
oxidation of the major intracellular reducing agent glutathione to glutathione disulfide 
with concomitant production of reactive oxygen species. Data from ref 77. 
 
We started this section by stating that the advent of bioorganometallics provides the 
medicinal chemist with access to new types of reactivity and therefore with new 
opportunities for anticancer drug design. Our studies on the ruthenium-arene 
anticancer drugs and results by others show that ruthenium-based compounds in 
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particular do live up to this expectation. The general structure of the ruthenium-arenes 
provides a versatile platform for structural modification and activity optimization. 
Correlating structure and reactivity with cytotoxicity is complicated, but some general 
trends can be discerned. This way, control can be exerted over some kinetic (e.g. 
hydrolysis rate) and thermodynamic (pKa, specific binding interactions) parameters 
that govern both activation of the drug and the strength of the interaction with cellular 
targets. It is interesting to note here that not only the complexes on the (relatively) fast 
side of the scale of ligand-exchange exhibited good cytotoxicity. Some kinetically 
inert complexes proved equally cytotoxic and presumably operate through completely 
different, non-classical mechanisms of action. A good example of the latter is the 
simultaneous depletion of GSH with concomitant generation of ROS by a 
catalytically active Ru(II)-arene anticancer agent (77). These results show the scope 
for design of ruthenium-arene anticancer drugs, and in particular their ability to 
operate in ways beyond the classical cisplatin-paradigm of selective DNA-binding. 
A major aim that needs to be addressed in future work is the targeted delivery of 
organometallic anticancer drugs to cancer cells only. Also, additional features that 
generate cytotoxic activity other than disruption of DNA replication, such as the 
inclusion of molecular fragments that can interfere in cancer cell-specific cellular 
pathways, could be explored (11, 103). 
 
IV. Osmium(II)-Arenes: A cytotoxic family of the heavier congener 
 
The application of organometallic complexes of the other group 8 elements, iron and 
osmium, in anticancer drug design has until recently been almost exclusively focused 
on iron, with the ferrocenyl derivative of tamoxifen (ferrocifen) being the most 
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prominent example (104). Organometallic osmium compounds have been little 
explored in this respect. 
We have recently extended our interest to the analogous half-sandwich osmium-arene 
complexes and are exploring the chemical and biological properties of [Os(
6
-
arene)(XY)Z]
n+
 complexes (Figure 25) (105). Both the aqueous chemistry and the 
biological activity of osmium complexes have been little studied. Third row transition 
metals are usually considered to be more inert than those of the first and second rows. 
Similar to the five orders of magnitude decrease in substitution rates of Pt(II) 
complexes compared to Pd(II), the [Os(
6
-arene)(L)X]
n+
 complexes were expected to 
display rather different kinetics than their Ru(II)-arene analogues. A few other reports 
on the anticancer activity of osmium-arene complexes have also appeared recently 
(106-108). 
 
Structure and Reactivity. In our initial studies (105), we looked at the structure and 
reactivity of [OsCl(L)(
6
-arene)]
n+
 with N,N-chelating ligand en (26) and O,O-
chelating ligand acac (27a,b) (Figure 25). X-ray crystal structure determinations 
showed the complexes to be isostructural with their ruthenium analogues, with the 
same M–Cl bond lengths, even though the ligand exchange rates are different (vide 
infra) (Figure 24). The hydrolysis of [Os(
6
-bip)Cl(en)]
+
 (26) is ca. 40 times slower 
(t½ 6.4 h) than that of its Ru(II) analogue 10, consistent with often-observed slower 
exchange rates on osmium compared to ruthenium. 
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Figure 24. Comparison between the osmium- and ruthenium-arenes, exemplified by 
the respective [M(
6
-bip)Cl(en)]
+
 complexes. Although the crystal structures show 
the complexes to be isostructural with similar M–Cl bond lengths (a), the properties of 
the complexes are quite different, illustrated by the differences in hydrolysis rate (t1/2), 
pKa and 5′-GMP binding (the black box denotes the amount of OPO3-bound 5′-GMP), 
(b). 
 
It is interesting, however, that similar water exchange rates have been reported for the 
Os(II) and Ru(II) complexes [M(
6
-benzene)(OH2)3]
2+ 
(109), indicative of a major 
influence of the chelating ligand. Indeed, changing the chelating ligand to acac 
resulted in a significant increase in rate and extent of aquation. DFT calculations show 
that aquation of [Os(
6
-arene)Cl(L)] is indeed more facile for L = acac compared to L 
= en, and the mechanism is more dissociative in nature (110). However, hydroxido-
bridged dimers [Os2(
6
-arene)2( -OH)3]
+
 play a dominant role in the aqueous 
chemistry of [Os(acac)(
6
-arene)Cl] (27a,b), whereas they are only a minor 
component, and then only at high pH, in the ruthenium systems (Figure 25). The 
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hydroxido-bridged dimer is the only species present on dissolution of [Os(acac)Cl(
6
-
p-cym)] (27a) at micromolar concentrations, conditions relevant for biological testing. 
The pKa values of the aqua complexes are all significantly lower (ca. 1.5 units) than 
those for the corresponding ruthenium-arene complexes, e.g. 6.34 for [Os(
6
-
bip)(en)(OH2)]
2+
 and 7.12 for [Os(acac)(
6
-bip)(OH2)]
+
. Therefore, at physiological 
pH almost all of the hydrolyzed en complex would be present in the hydroxide form, 
[Os(
6
-bip)(en)(OH)]
+
. The higher acidity of osmium arene aqua complexes proved to 
be general and can be attributed to increased mixing of the * (Os)   (OH
-
) 
orbitals (105). 
 
The aqueous chemistry of N,O-chelated complexes appeared to be intermediate 
between that of the neutral N,N-chelates and anionic O,O-chelates, with significant 
effects of the chosen N- and O-group (111).  The aminoacidate complexes hydrolyzed 
rapidly, but replacement of the primary amine by the -acceptor pyridine slowed 
down the rate of hydrolysis. Important was the observation that the inactive 
aminoacidate complexes again proved unstable with respect to hydroxido-bridged 
dimer formation, whereas no such dimer formation was observed with the active pico 
(28) and oxine (30) complexes (vide infra for cytotoxicity). The strength of the Os–
N(pyridine) bond seems crucial for the stability of the complex. At high chloride 
concentrations typical of blood plasma (ca. 100 mM) the complex [OsCl(
6
-p-
cym)(pico)] (28a) is likely to be mainly present as the less reactive intact chlorido 
species. At lower [Cl
-
] concentration (4 mM, typical of cell nucleus), the complex is 
activated by hydrolysis. As previously stated for the ruthenium-arenes this presents an 
interesting prodrug activation strategy for DNA binding. 
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Figure 25. a) General aqueous reactivity of osmium(II)-arenes: the formation of a 
hydroxido-bridged dimer can play a major role in the aqueous chemistry of 
osmium(II)-arenes, especially if the chelate XY is an O,O-bidentate ligand; b) 
molecular structures of the osmium-arene anticancer agents 26-30. 
 
Nucleobase Binding. Nucleobase interactions showed slow interaction of [Os(
6
-
bip)Cl(en)]
+
 (26) with 9-EtG and then only to a limited extent (45% after 22 h). No 
binding to Ado, Cyt or Thy was observed. [Os(acac)(
6
-bip)Cl]  (27b) on the other 
hand binds rapidly to both 9-EtG and Ado (< 10 min), but not to Cyt or Thy. Notably, 
the hydroxo-bridged dimer was inert towards nucleobases (105). Two major adducts 
were observed in the reaction between [Os(
6
-bip)Cl(en)]
+
 (26) and 5′-GMP 
attributable to N7 and phosphate adducts, which formed in a 2:1 N7/phosphate ratio 
(112) (Figure 24). Only about 40% of 5′-GMP is bound after 30 h. This contrasts with 
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the 5′-GMP binding of [Ru( 6-bip)Cl(en)]+ (10), for which quantitative and almost 
selective binding to N7 is observed after 1 d (81). 
Nucleobase competition binding experiments showed binding of [OsCl(
6
-p-
cym)(pico)] (28a) to both G and A, but with a strong preference for G (111). 
Intriguingly, a modest binding constant for G binding was found (log K 3.95), but the 
slow dissociation of 9-EtG at micromolar concentrations, makes it likely for G 
adducts on DNA or RNA to persist once formed. Little and no binding to the 
pyrimidine bases Cyt and Thy was observed. 
 
Cytotoxicity. [OsCl(acac)(
6
-arene)] (27a,b) showed no cytotoxicity towards A2780 
and A549 cell lines, probably attributable to formation of the inert hydroxido-bridged 
dimer. Replacement of acac for the potentially more stable five-membered chelate 
ring of maltolato did provide some stabilization towards dimer formation compared to 
the acac complex, but under biologically relevant conditions the hydroxido-bridged 
dimer remained the dominant species (110).  Although the complexes were not active, 
the results did show that kinetics of ligand substitution on osmium can be controlled 
by variation of the ligand and thus proved very valuable for our further studies.  
 
Initial experiments showed that [Os(
6
-bip)Cl(en)]
+
 (26)
 
was not cytotoxic towards 
cancer cells (105), but a later reassessment of the cytotoxic activity of this compound 
showed that it indeed was active at micromolar concentrations (IC50 values of 7.6 
(A2780) and 10 M (A549)) (112). A possible explanation for the initial lack of 
activity may be the partial decomposition of the complex in stock test solutions 
prepared in DMSO, as was evidenced in subsequent studies (112). The cytotoxicity 
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data are now more in line with the chemical properties of the complex, i.e. observed 
hydrolysis rate and guanine binding. 
The use of an extended arene (tetrahydroanthracene) in [OsCl(en)(
6
-tha)]
+
 (29) gave 
rise to a similar potency (112). This contrasts the data for ruthenium-arenes, where the 
same substitution gave rise to a 10-fold increase in activity. Further work therefore 
needs to determine if the extended Os-arenes can intercalate into DNA in a manner 
similar to Ru-arenes. Replacement of the N,N-chelating ligand en for other N,N-
bidentates with pyridine, aliphatic amine or azopyridine donor atoms lead to loss of 
activity, probably because of slower hydrolysis and higher acidity of the coordinated 
water (112). 
 
Further ligand variation led to the isolation of other osmium-arenes with moderate to 
high cytotoxicity towards cancer cells (111). We found that the aqueous chemistry of 
the organometallic osmium complexes could be fine-tuned so as to achieve cancer cell 
cytotoxicity by using mixed N,O-chelate ligands. Several aminoacidates, picoline 
(pico) and 8-hydroxyquinoline (oxine) were tested, but inclusion of pyridine as the N 
donor rather than a primary amine proved key for cytotoxic activity. The complexes 
[Os(
6
-bip)Cl(pico)] (28b), [OsCl(
6
-p-cym)(pico)] (28a), and [OsCl(
6
-p-
cym)(oxine)] (30) exhibit cytotoxic activity against human ovarian (A2780) and lung 
(A549) cancer cells, with IC50 values of 5-60 M. Notable is the high activity of 
[Os(
6
-bip)Cl(pico)] (28b) with IC50 values of 4.2 (A2780) and 8 M (A549) (111). 
The four active complexes [Os(
6
-bip)Cl(en)]
+
 (26), [Os(
6
-bip)Cl(pico)] (28b), 
[OsCl(
6
-p-cym)(pico)] (28a), and [OsCl(
6
-p-cym)(oxine)] (30) all show similar 
potency towards cisplatin-sensitive and resistant A2780 cell lines, indicating a 
different detoxification mechanism than cisplatin. Intriguingly, [Os(
6
-bip)Cl(en)]
+
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(26) shows an even greater activity in the resistant cell line (resistance factor 0.55) 
(113). 
 
Figure 26. Bar charts relate the influence of different chelates in [Os(
6
-
arene)Cl(XY)]
n+
 (XY = N,N- N,O- or O,O-) on cytotoxicity, stability with respect to 
hydroxido-dimer formation, hydrolysis rates, and pKa of the aqua adduct for osmium-
arene complexes. Shading indicates the range in observed values. Adapted from ref. 
111. 
 
DNA binding. An in-depth study of osmium-arene anticancer drug binding to DNA 
was carried out in collaboration with the group of Brabec (113). It is notable that the 
tested complexes all bind polymeric DNA. The complexes [Os(
6
-bip)Cl(pico)] (28b) 
and [OsCl(
6
-p-cym)(oxine)] (30) bind rapidly to CT DNA (t½ ca. 2 h. at ri = 0.1), 
whereas [Os(
6
-bip)Cl(en)]
+
 (26)  and [OsCl(
6
-p-cym)(pico)] (28a) bind up to two 
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and four times more slowly with t½ values of 4.6 and 8.3 h, respectively (113). For 
comparison, the t½ of DNA binding of the ruthenium-arene [Ru(
6
-bip)Cl(en)]
+
 is ca. 
10 min, approximately 28 times faster than its osmium analogue, which might allow 
more of the latter to reach its target site (88). The extent of DNA binding ranges from 
ca. 72% for [OsCl(
6
-p-cym)(pico)] (28a) to 95% for [Os(
6
-p-bip)Cl(pico)] (28b), 
illustrating the importance of an extended arene ring for DNA binding. RNA 
synthesis transcription mapping showed the major stop sites to be guanine residues 
(with some minor ones as adenine), similar to cisplatin and the ruthenium analogues. 
Electrophoretic mobility experiments on osmium-adducts of DNA duplex 
oligonucleotides (up to 21 bp) showed that no DNA bending is induced upon osmium 
binding. The binding of the osmium-arene complex leads to a large degree of 
unwinding (21-27°) (except for the oxine complex) (113), much larger than that 
observed for ruthenium(II) complexes (88), This large unwinding angle might be 
explained by an additional interaction of the arene ligand with the duplex upon strong 
binding of osmium. The complex [OsCl(
6
-p-cym)(oxine)] (30) on the other hand 
shows hardly any significant unwinding of DNA (< 2.5 °). This suggests that this 
complex interacts with DNA in a different manner, which could correlate with its 
markedly lower cytotoxic activity (113). 
 
In line with expectations of kinetic inertness of third-row transition metals, little 
interest has been vested in the development of osmium anticancer drugs, as ligand-
exchange rates did not seem favorable on the timescale of cellular processes. Our 
work, however, shows that the kinetic lability of such complexes can be tuned to such 
extent that anticancer activity comes within range. We have demonstrated how 
rational chemical design can thus be applied to osmium-arene complexes resulting in 
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specific windows of reactivity, stability, and cancer cell cytotoxicity (111). This has 
allowed us to design complexes with cytotoxicities comparable to their ruthenium 
analogues, but with reactivities that are 100 times less. Such a range of kinetic effects 
can be useful for balancing cytotoxicity and unwanted side-effects of anticancer 
drugs, as illustrated previously by the clinical profiles of cisplatin and the less-labile 
second generation drug carboplatin (112). The osmium complexes are therefore 
interesting candidates for further investigation. 
 
V. Concluding Remarks 
 
In general transition metal complexes provide enormously versatile platforms for drug 
design. Many variations in the metal itself, the types and numbers of coordinated 
ligands and hence in the strengths of coordination bonds and in the kinetics of ligands 
substitution processes are available. In this review, we have highlighted our efforts 
towards the development of photoactive platinum anticancer agents and the 
ruthenium- and osmium-arene families of anticancer agents. The key to successful 
design of clinically useful drugs is effective activity whilst minimizing side effects. 
Targeting is important to ensure that sufficient amounts of the active drug reach the 
target site and that unwanted reactions do not occur along the way. Hence both the 
thermodynamics and kinetics of ligand exchange and redox processes must be 
carefully controlled. This presents a major challenge for the transition metal medicinal 
chemist- an exciting one too. We have shown that such control is indeed possible by 
systematic ligand variation. This way we were able to design photoactive 
platinum(IV) complexes that are stable and non-toxic in the dark. The strategy of 
activation by light to yield highly cytotoxic species at irradiated spots only allows for 
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local, targeted treatment and holds the promise of less invasive chemotherapy. 
Similarly, our work on the ruthenium- and osmium-arenes showed that 
thermodynamic and kinetic parameters, such as those associated with aquation, can 
vary over several orders of magnitude, thus allowing the chemist to fine-tune the 
properties of the agent for increased cytotoxicity. Not only is direct coordination to 
the metal important in biological recognition processes but so are second coordination 
sphere interactions, e.g. H-bonding, hydrophobic interactions, as exemplified by the 
stereospecific hydrogen bonding interactions of the ruthenium-arenes and arene 
intercalation upon coordination of the complex to DNA. 
 
While for the photoactive Pt(IV) complexes both metal- and ligand-centered redox 
reactions can be involved in biological mechanisms of action, it is interesting to note 
that ligand-centered redox processes can also dominate reactions of arene complexes. 
The catalytic depletion of GSH by azopyridine complexes with concomitant 
generation of ROS, for instance, is a ligand-based process, which is nonetheless 
modulated and made possible by coordination of the ligand to ruthenium. Such 
reactions are often not possible for the ligands alone in purely organic drugs. 
Additionally, metal complexes themselves are renowned as catalysts and the 
possibility of designing catalytically-active metallo-drugs which are not prematurely 
poisoned in the biological system represents a significant challenge. 
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